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ABSTRACT 
 
WNT5A SIGNALING INDUCED PHOSPHORYLATION INCREASES ACYL PROTEIN 
THIOESTERASE 1 ACTIVITY AND PROMOTES MELANOMA METASTATIC BEHAVIOR 
Rochelle Shirin Sadeghi 
Dr. Eric S. Witze 
Wnt5a has been implicated in melanoma progression and metastasis, although the exact 
downstream signaling events that contribute to melanoma metastasis are poorly understood. 
Wnt5a signaling results in acyl protein thioesterase 1 (APT1) mediated depalmitoylation of pro-
metastatic cell adhesion molecules CD44 and MCAM, resulting in increased melanoma invasion. 
The mechanistic details that underlie Wnt5a-mediated regulation of APT1 activity and cellular 
function remains unknown. Here, we show Wnt5a signaling regulates APT1 activity through 
induction of APT1 phosphorylation and we further investigate the functional role of APT1 
phosphorylation on its depalmitoylating activity. We found phosphorylation increased APT1 
depalmitoylating activity and reduced APT1 dimerization. We further determined APT1 
phosphorylation increases melanoma invasion in vitro and is also correlated with increased tumor 
grade and metastasis. Our results further establish APT1 as an important regulator of melanoma 
invasion and metastatic behavior. Inhibition of APT1 may represent a novel way to treat Wnt5a 
driven cancers. 
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CHAPTER 1: MELANOMA AND THE ROLE OF WNT5A SIGNALING 
 
OVERVIEW 
 Melanoma, the deadliest form of skin cancer, is caused by the transformation of 
melanocytes, or the pigment-producing cells in the skin. With over 90,000 new 
melanomas being diagnosed this year, and the rates of melanoma rising over the past 
30 years, it’s clear that this disease is a significant health concern that needs to be 
addressed (American Cancer Society). With a 5-year survival rate of only 17% for 
metastatic melanoma patients, it is imperative we fully understand the downstream 
signaling events that are promoting melanoma metastasis, so we can create more 
targeted therapies for patients. Several in vitro studies and observations of clinical data 
have suggested a role for Wnt5a signaling in melanoma metastasis. Here, we provide 
relevant background information important to understand and present other findings that 
draw a parallel of Wnt5a signaling to melanoma metastasis.   
 
MELANOMA 
 Melanocytes are specialized pigment-producing cells in the basilar epidermis of 
the skin. Their main biological function is to provide melanin pigment to their neighboring 
keratinocytes (Shain, A. and Bastian, B., 2016). Melanocytes are neural crest-derived 
cells and during development, they colonize throughout the skin, eye, and to a lesser 
extent, other areas of the body (Mort et al., 2015). Understanding the biology of 
melanocytes, and the genes and pathways that regulate melanocytes is key to 
understanding melanoma development. 
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 Melanocytes typically divide infrequently (Jimbow et al., 1975). Melanocyte 
proliferation and pigment production are itself stimulated by UV-radiation. They then 
produce and provide melanin to keratinocytes, which provides protection from UV 
radiation-induced DNA damage (Costin, G-E.E., Hearing, V.J., 2007). UV radiation-
induced DNA damage results in secretion of the α-melanocyte stimulating hormone 
(αMSH), αMSH then binds to the melanocortin 1 receptor (MC1R) expression on 
melanocytes and induces synthesis of melanin pigment. Melanocytes then deliver the 
melanin to keratinocytes where it scatters and absorbs UV radiation. In addition, 
keratinocytes use melanin to protect their nucleus from receiving further UV radiation-
induced DNA damage.  
 Melanocytic naevi are benign proliferations of melanocytes and are also referred 
to as naevi in the radial growth phase. Nevertheless, naevi in the radial growth phase 
have a low potential to metastasize and stop proliferation. Many different types of 
mutations can be responsible for the benign proliferation. Activation of BRAF is among 
the most frequent in melanoma, specifically the constitutively activated mutant 
BRAFV600E. When a naevus accumulates genetic alterations, through activation 
mutations of BRAF or NRAS for example, it can result in increased proliferation and 
benign naevi progressing to a dysplastic naevus. The most recurrent somatic mutations 
affect genes in key signaling pathways that govern proliferation (BRAF, NRAS), growth 
and metabolism (PTEN, KIT), resistance to apoptosis (TP53), cell cycle control 
(CDKN2A), and replication (TERT) (Shain et al., 2016). Through more genetic 
alterations, such as the ones just mentioned, it can progress to a melanoma that 
remains localized. Some common mutations responsible for this phase of progression 
are TERT mutations, deletions of CDKN2A, disabling mutations and deletions of PTEN 
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or TP53. Through mechanisms not well understood, but generally, by acquiring 
mutations over time, the melanoma can begin vertical growth phase. This is the phase 
where the melanoma has now breached the basement membrane and begins to 
metastasize by entering the bloodstream. We are particularly interested in determining 
the molecular ‘switch’ that drives radial growth to vertical growth of melanomas. 
 With the 5-year survival rate dramatically decreasing as tumor stage increases, 
investigating the mechanism driving melanoma metastasis is important to better 
understand the driving forces behind melanoma metastasis (Sandru et al., 2014). 
Several studies have demonstrated an important role for Wnt5a in cancer. Previously, 
the elevated expression of Wnt5a in melanoma samples and subsequent in vitro studies 
have suggested a role for Wnt5a in melanoma metastasis. Important findings include: 
Wnt5a expression correlating with increased melanoma tumor grade and decreased 
melanoma patient survival, Wnt5a signaling increasing melanoma migration, motility, 
and invasion, and suggestions of Wnt5a expression to be used as a clinical risk factor 
(Bittner et al., 2000; Weeratna et al., 2002; Carr et al., 2003; Da Forno et al., 2008). With 
our research, we aim to provide clarity in understanding the mechanism of how Wnt5a 
signaling is promoting an aggressive phenotype in melanoma. 
 
WNT5A SIGNALING  
 Wnt proteins are secreted glycoproteins that regulate multiple signaling 
pathways. There are 19 Wnt members in mice and humans, with unique expression 
patterns across tissues and various functions in development. They bind to the 10 
members of the transmembrane Frizzled (Fz) family of G-protein-coupled receptors and 
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co-receptors that include Ror family members. Wnt5a is a secreted ligand responsible 
for a non-canonical Wnt signaling pathway to regulate cell polarity and cell migration. 
Upon interaction with its Frizzled receptor, it activates a signal transduction cascade that 
results in cell migration, invasion, among other changes in cell behavior (Sato et al., 
2010). Multiple studies have suggested ROR2 acts as a co-receptor for Wnt5a and 
deemed it necessary for the events downstream that promote melanoma metastatic 
behavior (Sato et al., 2009; O’Connell et al., 2009). The initial indication that Wnt5a 
signaling is able to regulate cell migration came from the observation that Wnt5a 
signaling is responsible for convergent extension in Xenopus embryos (Du et al., 1995). 
Convergent extension is a developmental process driven by migration of polarized cells 
leading to narrowing and lengthening during morphogenesis. In WNT5A-/- knockout 
mice, phenotypes include shortened anterior-posterior body axis, truncation of the 
proximal skeleton in the limbs, an absence of distal digits, and the loss of polarized 
movement and directional cell growth (Yamaguchi et al., 1999). Wnt5a can regulate 
distinct pathways by binding to Frizzled2 (Fzd2). By competing with the canonical Wnt 
ligand, Wnt3a, for Fzd2 binding, Wnt5a can inhibit the Wnt3a-dependent accumulation of 
β-catenin and phosphorylation of LRP6 (Sato et al., 2009). Wnt5a signaling controls cell 
polarity and directional cell movement and Wnt5a treatment can promote the recruitment 
and reorganization of proteins involved in cell adhesion and cell signaling (Witze et al., 
2008, Wang et al., 2015). Recruitment and reorganization of actin, myosin IIB, Frizzled3, 
and melanoma cell adhesion molecule becomes accumulated asymmetrically at the cell 
periphery to control cell orientation, polarity, and directional movement in response to 
Wnt5a gradients (Witze et al., 2008). Additionally, Wnt5a signaling can activate the 
Wnt/Ca2+ pathways. Wnt5a signaling results in elevation of free Ca2+ levels to induce 
Ca2+ signaling in a polarized manner (Witze et al., 2013). This calcium flux can result in 
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the activation of several signaling pathways, such as protein kinase C (PKC), 
calcium/calmodulin-dependent protein kinase II (CAMKII), and JUN N-terminal kinase 
(JNK) (Kohn, A. and Moon, R., 2005). In this way, Wnt5a signaling itself can result in 
regulation of various downstream players. 
Dishevelled, also known as Dvl, is a scaffold protein that has been shown to be 
essential in Wnt signaling, across canonical, non-canonical, and planar cell polarity 
pathways (Liu, et al., 2001; Willert et al., 2003; Wallingford, J. B., and Habas, R., 2005). 
It is understood that Dvl functions as a scaffold that brings receptors and downstream 
targets together. Wnt5a-Ror signaling has been shown to result in phosphorylation of 
Dvl, and it is suggested that Dvl phosphorylation might be a molecular switch that 
determines its function for the various downstream targets of these pathways (Ho et al., 
2012). Dvl is also able to activate the Wnt-Ca2+ pathway, as determined by Ca2+ flux, 
PKC, and CAMKII, making it a component of all reported Fz signaling pathways 
(Sheldahl et al., 2003). 
Wnt5a signaling can also result in APT1 mediated depalmitoylation of cell 
adhesion molecules MCAM and CD44, resulting in their asymmetric localization and 
increased melanoma invasion (Wang et al., 2015).  With this observation, Wnt5a 
signaling can result in depalmitoylation of cell adhesion molecules to change cell 
behavior. 
 
APT1 MEDIATED DEPALMITOYLATION 
 Palmitoylation, also known as S-acylation, is the reversible addition of a 16-
carbon fatty acid to cysteine residues via a thioester bond. Palmitate addition is 
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mediated by palmitoyltransferases, (PATs) that belong to the DHHC (aspartate-histidine-
histidine-cysteine) family. Palmitate removal is mediated by acyl-protein thioesterases 
(APTs). Dynamic changes in protein S-palmitoylation are required for signal 
transduction. Proteins can be modified with lipid attachments to regulate membrane 
localization and function. Not only can palmitoylation allow proteins to become 
associated with membranes, but palmitoylation can also modulate protein behavior and 
function, especially in the case of integral membrane proteins.  
 Although there is a certain degree of redundancy among PAT enzymes, some 
particular substrates have been shown to be dependent on an individual PAT for their 
modification (Chamberlain, L. H., and Shipston, M. J., 2015). While humans have 23 
PATs, there are only two cytoplasmic APTs have been described in detail: APT1 and 
APT2 (Duncan et al., 1998; Tomatis et al., 2010; Lin et al., 2015; Zeidman et al., 2009). 
Although APT1 and APT2 share 64% homology, they are thought to be selective since 
they have different substrate specificity and since they can be inhibited with isoform-
selective inhibitors, ML348 and ML349, respectively (Tomatis et al., 2010; Tian et al., 
2012; Rusch et al., 2011; Won et al., 2016). APT1 and APT2 contain a catalytic triad 
consisting of a serine, a histidine, and an aspartic acid (Wang et al., 1997a; Wang et al., 
1997b; Devedjiev et al., 2000; Won et al., 2016).  
Other depalmitoylases exist in the cell, such as the newly identified ABDH17 
hydrolase responsible for depalmitoylation of N-Ras resulting in re-localization to internal 
cellular membranes and the lysosomal hydrolase PPT, which removes palmitates from 
proteins in lysosomes (Lin et al., 2015, Verkruyse, L. and Hofmann, S., 1996). However, 
we focus our studies on APT1 regulation due to the following findings: Wnt5a signaling 
results in APT1 mediated depalmitoylation of cell adhesion molecules MCAM and CD44, 
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APT1 overexpression leads to increased melanoma invasion, and conversely, 
knockdown of APT1 inhibits melanoma invasion (Wang et al., 2015). Since upregulated 
Wnt5a expression and activation of Wnt5a signaling is observed in human patient 
samples and results in increased melanoma migration and invasion, and we can see 
similar responses when modulating APT1 expression, we focus our attention on how 
Wnt5a signaling may be regulating APT1 activity and function. With the observation of 
Wnt5a treatment increasing APT1-mediated depalmitoylation of cell adhesion molecules 
MCAM and CD44 and promoting an invasive phenotype through APT1, we hypothesized 
APT1 mediated depalmitoylation is regulated by Wnt5a signaling by a post-translational 
modification to increase APT1 depalmitoylating activity, and elevated Wnt5a/APT1 
signaling is responsible for an aggressive melanoma metastasis phenotype.    
 
WNT5A SIGNALING IN CANCER 
 Wnt proteins are a family of ligands whose functions are well known in embryonic 
systems development but are increasingly being recognized as key proteins in cancer. 
Although, its role in cancer is not well understood. Aberrant Wnt5a expression has been 
characterized in a wide variety of tumor types (Iozzo et al., 1995). Wnt5a has not only 
been correlated with increased tumor grade or decreased patient survival in melanoma 
patients (Bittner et al., 2000; Carr et al., 2003; Da Forno et al., 2008). Not only is 
Wnt5a’s expression pattern correlated with tumor progression, but Wnt5a expression 
can lead to other events that contribute to invasiveness, such as upregulation of 
metastasis-associated molecules like CD44, initiation of epithelial to mesenchymal 
transition (EMT), and downregulation of metastasis suppressors (Dissanayake et al., 
2007).  
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 Wnt5a has been proposed as a metastatic melanoma mediator, and further 
evidence has been uncovered to support that proposal. One of its co-receptors, the 
transmembrane tyrosine kinase receptor ROR2, is expressed predominantly in 
metastatic melanoma samples, correlates with Wnt5a expression, and is regulated by 
Wnt5a expression (O’Connell et al., 2009). Also proposed in that study is the necessity 
of ROR2 for Wnt5a-mediated metastasis in melanoma (O’Connell et al., 2009). If this 
pathway is repressed through inhibition of various points along the pathway and utilizing 
different tools, such as knockdown of ROR2, or by inhibiting or knockdown of Frizzled 
receptors, melanoma invasion is reduced. Furthermore, inhibition of Wnt5a signaling 
with Wnt5a-derived N-butyloxycarbonyl hexapeptide, termed Box5, inhibited migration 
and invasion of Wnt5a expressing HTB63 melanoma cells by inhibition of Wnt5a-
induced protein kinase C and Ca2+ signaling, which has been demonstrated to be 
essential for cell invasion (Jenei et al., 2009).  
Wang et al., 2015 defines some of the downstream events that are playing a role 
in melanoma metastasis that had not been previously described. Notably, as mentioned 
above, Wnt5a signaling increasing APT1 mediated depalmitoylation of the cell adhesion 
molecules MCAM and CD44. MCAM, also known as Melanoma Cell Adhesion Molecule 
or CD146, is an integral membrane protein consisting of an extracellular fragment 
containing an immunoglobulin-like domain that responds to the extracellular 
environment, a transmembrane region, and short cytoplasmic tail (Lehmann et al., 
1989). Remarkably, MCAM is strongly expressed in metastatic lesions and advanced 
primary tumors but rarely detected in benign tissue or neighboring untransformed 
melanocytes (Lehmann et al., 1987). MCAM is also expressed in endothelia of blood 
vessels penetrating primary and metastatic melanoma and in a variety of carcinomas in 
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addition to melanoma (Johnson et al., 1996). Subsequent studies have suggested 
MCAM has a potential marker for tumor diagnosis, prognosis, and treatment (Johnson et 
al., 1996; Shih, I.M., 1999; Wu, G.J., 2012). 
WM239A cells expressing an MCAM palmitoylation mutant, MCAMC590G, is 
sufficient to polarize MCAM localization, similar to what is observed with Wnt5a 
treatment, suggesting MCAM depalmitoylation is what is allowing MCAM to be 
asymmetrically localized (Wang et al., 2015). Expression of the MCAM palmitoylation 
mutant alone is sufficient to promote cell invasion in vivo, as determined by a xenograft 
tumor model (Wang et al., 2015). Moreover, Wnt5a binds to CD146 (MCAM) to regulate 
cell migration and zebrafish embryonic convergent extension, and it is suggested CD146 
can act as a Wnt5a receptor in regulating cell migration (Ye et al., 2013). 
CD44 is an important cell adhesion molecule and is a major receptor for the 
extracellular matrix component hyaluronan, can act as co-receptor for growth factors, 
and can reorganize the cytoskeleton through interaction with cytoplasmic linker proteins 
(Orian-Rousseau et al., 2002; Ponta et al., 2003). CD44 is a class I transmembrane 
glycoprotein that mediates the response to the environment. The cytoplasmic-tail region 
can interact with ankyrin to mediate hyaluronan-dependent cell adhesion, and ERM 
proteins (ezrin, radixin, and moesin) to crosslink the actin cytoskeleton to CD44 (Ponta 
et al., 2003). CD44 has been implicated in progression for a wide variety of cancers. 
CD44 is a key regulator of migration and is enriched in cholesterol-enriched membrane 
microdomains, termed lipid rafts. Lipid raft affiliation of CD44, through palmitoylation, 
negatively regulates interactions with its migratory binding partner ezrin (Babina et al., 
2014). Mutation of CD44 palmitoylation sites, Cys286 and Cys295, also has a similar 
effect to what is observed with MCAM palmitoylation mutants. CD44 palmitoylation 
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mutants reduced lipid raft affiliation in invasive MDA-MB-231 breast cancer cells, 
increased CD44-ezrin co-precipitation, and enhanced cell migration (Babina et al., 
2014). This inhibition of CD44 palmitoylation was sufficient to induce the phenotypic 
appearance of epithelial-to-mesenchymal transition (EMT) and increase cell motility 
(Babina et al., 2014). Notably, levels of palmitoylated CD44 were lower in primary 
cultures from invasive ductal carcinomas relative to the non-invasive tissue, providing 
the clinical data that in combination with the in vitro observations, suggests a role for 
CD44 palmitoylation and cancer progression. These results suggest both MCAM and 
CD44 depalmitoylation plays a role in promoting invasive behavior and metastasis.   
 Previously, it has been proposed that Wnt5a could be a potential therapeutic 
target for BRAFi-resistant melanoma (Prasat et al., 2015). Patients who develop 
resistance to standard of care BRAF inhibitors stand to be in dire need of another 
therapeutic option. Wnt5a inhibition may be a novel way to treat BRAFi resistant tumors 
and can be an option for other melanoma patients who have elevated Wnt5a expression. 
This theory is discussed in greater detail in Chapter 5. Based on my own studies 
described below, APT1 presents itself as an alternative treatment option. In subsequent 
chapters, we outline the studies and evidence behind that proposal. 
Many other studies have begun to investigate Wnt5a’s role in other cancer types. 
Wnt5a expression was investigated in a large cohort of epithelial ovarian cancer patient 
samples and found to be upregulated in all major subtypes of epithelial ovarian cancer 
compared to borderline tumors or benign controls (Ford et al., 2014). Integrated 
transcriptomic and epigenomic analyses uncovered a transcriptional program driving 
Wnt5a-mediated glioblastoma stem cell (GSC) differentiation into endothelial-like cells, 
recruitment of endothelial cells to promote satellite lesions, which provided support for 
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invasive glioma cells away from the primary tumor in a de novo glioblastoma multiforme 
(GBM) model (Hu et al., 2016). Interestingly, clinical data reveal higher Wnt5a 
expression in peritumoral and recurrent GBMs relative to primary GBMs. These results 
suggest a role for Wnt5a-mediated glioblastoma stem cell differentiation and invasive 
growth in disease recurrence. Additionally, treatment of ovarian surface epithelial cells 
with Wnt5a decreased cell adhesion and was associated with increased epithelial to 
mesenchymal transition (EMT) (Ford et al., 2014). Wnt5a and ROR2 expression are also 
correlated with a poor prognosis in non-small cell lung cancer patients (NSCLC) (Lu et 
al., 2015). Likewise, ROR2 can regulate migration in osteosarcomas (Dai et al., 2017). 
Wnt5a overexpression increased clone formation, migration, invasion, and promoted 
EMT and metastasis in NSCLC (Wang et al., 2017). Since Wnt5a seems to be playing a 
role in a wide variety of cancer types, by specifically modulating migration, invasion, and 
metastasis, it is imperative we fully understand the downstream signaling events that are 
contributing to tumor progression and metastasis.  
All of this evidence presented thus far combined suggests that Wnt5a signaling 
mediates melanoma metastasis among other cancer types besides melanoma. Previous 
data suggests Wnt5a induced APT1-mediated depalmitoylation of cell adhesion 
molecules might play a role in driving melanoma metastasis. However, prior to the 
publication of this thesis work detailed in Chapter 3, the exact details of how APT1 is 
regulated by Wnt5a signaling remained unknown. Nevertheless, we aim to investigate 
the mechanism by which Wnt5a signaling is regulating APT1 activity and function, and 
how activation of this signaling pathway is promoting metastatic behavior. 
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THESIS OBJECTIVES 
 Prior to this thesis project, there was a gap in the literature in understanding the 
how Wnt5a signaling is regulating APT1 activity and function and the downstream 
events that lead to increased migration, invasion, and promotion of metastasis. The 
overarching hypothesis of this thesis project was that Wnt5a signaling induces 
phosphorylation of APT1, thus increasing its depalmitoylating activity. Increased APT1 
depalmitoylating activity results in increased depalmitoylation of cell adhesion molecules, 
driving increased melanoma invasion, and ultimately the promotion of melanoma 
metastasis. With more details of the Wnt5a signaling pathway uncovered in this research 
paper, we aim to provide clarity and significance in targeting the Wnt5a pathway as a 
therapeutic avenue worth pursuing. Below is a picture of the model we are testing. 
 
?
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CHAPTER 2: CHARACTIZATION OF APT1’S ENZYMATIC ACTIVITY 
 
OVERVIEW 
 In the subsequent chapter, we dive into further detail on the previously reported 
mass spectrometry data that led us to conclude APT1 can be phosphorylated (see 
Chapter 3), but for the interests of explaining Chapter 2’s optimizations, we must clarify 
the APT1 tools we generated to study APT1’s depalmitoylating activity. We generated 
APT1 phospho-mutants to study the phosphorylation/de-phosphorylation states of APT1 
and the functional consequences of these modifications on its depalmitoylating activity. 
APT1 was previously reported to be phosphorylated on serine’s 209 and 210 in 
laryngeal cancer cells, although how APT1 became phosphorylated and how the 
phosphorylation state affected APT1’s activity and function remained unknown 
(Phosphosite.org, site group ID: 25299324 and 25299327). We mutated both of APT1’s 
detected phospho-site serine’s to alanine’s, APT1S209,210A, hereon referred to as APT1SA, 
so that it can no longer be phosphorylated and thus it is a phospho-deficient mutant. 
Conversely, we mutated serine 209 to an aspartic acid, APT1S209D, hereon referred to as 
APT1SD, to mimic the negative charge that would exist in the phosphorylated state of 
APT1 and thus it is a phospho-mimetic mutant. To address if Wnt5a signaling was 
regulating APT1 depalmitoylating activity, we needed an accurate and consistent assay 
to study and measure APT1’s depalmitoylating activity.  
 Previously, only a few assays had been developed that we could adapt to study 
APT1-mediated depalmitoylation and its enzymatic activity levels. In the attempt to 
finalize the assay we would use to study APT1-mediated depalmitoylation, we optimized 
a total of three different assays to find the most accurate representation of APT1’s 
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enzymatic activity. Here, we outline the various assays performed, describe the 
optimization techniques used, and final conclusions drawn from results. 
 
INTRODUCTION 
 Firstly, we tested a resorufin acetate hydrolysis assay that was previously used 
to measure hydrolase activity (Adapted from Hwang, S., 2015). The second assay we 
optimized was a fluorogenic palmitoyl-palmitoylation assay first characterized for 
lysosomal palmitoyl-protein thioesterase activity, or PPT found in the lysosome (Adapted 
from Van Diggelen et al., 1999). The final assay tested utilized synthetic small-molecule 
fluorophore depalmitoylation probe, or DPP-3 specifically, to monitor endogenous 
activity levels of S-palmitoylation (Kathayat et al., 2017). After careful interpretation of 
these assays, we concluded use of DPP-3 was the most accurate and consistent 
method to capture APT1’s depalmitoylating activity. In addition, we were able to use this 
substrate with purified proteins and in live cells in combination with live cell imaging 
microscopy, which will be discussed in greater detail in the following chapter. 
 
RESULTS 
 Resorufin acetate hydrolysis assay was originally developed to study hydrolase 
activity by using resorufin acetate as a fluorogenic substrate. In this assay, resorufin 
acetate (ResOAc) hydrolysis is measured as a proxy for APT1 enzymatic activity. 
Specifically, the acetyl group of ResOAc is hydrolyzed by APTs, producing a fluorescent 
Res- product, which has distinct fluorescent properties compared to the initial substrate. 
Using a Tecan plate reader equipped with excitation and emission filters of λex535(25) 
nm, λem590(20) nm respectively, you can measure the amount of product produced as a 
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means of analyzing the APT hydrolase activity (Figure 2.1A). Thus, the catalytic rate of 
APT1 is can be assayed by measuring the rate of fluorescent product production over 
time. One advantage of this technique was that it contained only a one-step reaction. 
However, there was not a palmitate group or another fatty acid group attached to the 
substrate. One could argue that it is too artificial since there is no real substrate 
specificity involved in the catalysis. APT1WT, APT1S209,210A, and APT1S209D were 
immunopurified from WM39A cells ectopically expressing wild-type APT1 or the APT1 
phospho-mutants. The reaction was performed using resorufin acetate and fluorescence 
was measured over time. All three samples had similar measurements that increased 
over time and no differences were observed between the wild-type APT1 and the APT1 
phospho-mutants (Figure 2.1B). Since this assay measures hydrolysis and the ResOAc 
substrate utilized is so dissimilar from a palmitoylated substrate, we concluded this 
assay might now be capturing an accurate representation of APT1’s depalmitoylating 
activity. We aimed to use a substrate that more closely mimics APT1’s palmitoylated 
substrates. 
 The fluorogenic palmitoyl-protein thioesterase assay was utilized next because of 
the artificial substrate contained a palmitoyl group. This assay was originally developed 
to study palmitoyl-protein thioesterase (PPT) activity from lysosomes (Van Diggelen et 
al., 1999). This assay also utilized a fluorophore synthetic substrate, although its 
structure differed considerably in terms of structure. To create the substrate, a palmitate 
group was added to the fluorochrome substrate 4-methylumbelliferyl-6-thiopalmitoyl-β-
glucopyranoside via a thioester bond to create Mu-6S-Palm-β-Glc. The addition of 
purified APT1, either purified from bacteria or immunopurified from melanoma cells, to 
the substrate results in a non-fluorescent cleaved intermediate from the removal of 
palmitate. A second reaction with β-glucosidase results in the final fluorescent product, 
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which can be observed at λ449nm (Figure 2.1C). We adapted this protocol with the 
purpose of using the assay for immunopurified APT1, as opposed to whole cell lysate, 
which was used in the original publication. APT1 was immunopurified from WM239A 
cells ectopically expressing APT1WT or phospho-dead APT1S209,210A and the two 
reactions were performed using increasing concentrations of the Mu-6S-Palm-β-Glc 
substrate. At lower concentrations of substrate, APT1WT and APT1S209,210A (hereon 
referred to as APT1SA) have similar activity. However, at the highest concentration 
APT1WT exhibited increased activity when compared to APT1SA (Figure 2.1D). When we 
tested APT1WT against phospho-mimetic APT1S209D (APT1SD), APT1SD had higher 
enzymatic activity compared to APT1WT, even at the lower concentrations of substrate 
(Figure 2.1E). When we treated WM239A cells ectopically expressing APT1WT or the 
catalytic inactive mutant APT1S119A with either purified Wnt5a or control buffer, then 
immunopurified APT1, and subsequently performed the fluorogenic palmitoyl-protein 
thioesterase assay, we observed increased depalmitoylation levels for Wnt5a-treated 
APT1WT but, observed no difference between Wnt5a untreated and untreated/treated 
catalytic inactive mutant APT1S119A (Figure 2.1F). These results suggest phospho-
mimetic APT1 exhibits increased activity, and mutation mimicking phosphorylation is 
sufficient to increase its activity. Moreover, the results suggest Wnt5a-treated APT1 also 
results in increased depalmitoylating activity. Advantages of using the fluorogenic 
palmitoyl-protein transferase assay was that this substrate contained a palmitate group, 
and thus this reaction involved recognition of a more physiologically relevant substrate. 
However, a potential pitfall, which proved to create much difficulty in attempting to obtain 
consistent results, was that this substrate had solubility issues and the protocol contains 
two reaction steps. Therefore, using the fluorogenic palmitoyl-transferase assay 
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increased the chances of variability across repeated experiments and reduced 
reproducibility among the results. We could observe differences between wild-type and 
mutants, but only at higher concentrations of Mu-6S-Palm-β-Glc, which proved difficult to 
work with at such high concentrations due to its solubility issues and we did not want to 
run the risk of testing with inaccurate concentrations of available Mu-6S-Palm-β-Glc if it 
were not to be solubilized completely. 
 Lastly, we discovered a recent publication utilizing small-molecular fluorophores 
to monitor the depalmitoylation activity levels of APTs, called depalmitoylation probes or 
DPPs (Kathayat et al., 2017). The authors of this paper state that development and 
application of DPPs provide the ability to measure endogenous levels of 
depalmitoylation activity in live cells. We contacted the authors of this paper and had 
their probe, DPP-3, synthesized for our studies. Similar to the previous assays, this 
reaction results in cleavage of a fluorescent product, which is then measured as a proxy 
for APT1 depalmitoylating activity. After addition of purified APT1 with DPP-3 substrate, 
fluorescence intensity is measured using Tecan plate reader at λex 490/9 nm and λem 
545/20 nm over time. Although it is not a palmitate, DPP-3 does have a fatty acid 
attached (Kathayat et al., 2017). This approach seems to be the best compromise of 
having a substrate that can be easily worked with, including its ability to be used in live 
cells, but also mimics APT1’s substrate as closely as possible. We expand more on this 
experiment, the applications of this probe, and its significance in Chapter 3. When we 
tested the depalmitoylating activity of wild-type APT1 and the APT1 phospho-mutants 
using DPP-3 as a substrate, we observed a significant increase of activity between 
APT1SD compared to APT1WT and negative control APT1S119A (Figure 2.1G). 
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Figure 2.1. Characterization and optimization of analyzing APT1’s depalmitoylating 
activity. (A) Schematic of resorufin acetate hydrolysis assay reaction. (B) 
Depalmitoylation activity measured by resorufin acetate hydrolysis assay of bacterially 
expressed and purified APT1WT, APT1S209,210A (APT1SA), and APT1S209D (APT1SD) 
measured over time. n=3 replicates per condition. (C) Schematic of fluorogenic 
palmitoyl-protein thioesterase assay reactions. Adapted from Van Diggelen et al., 1999. 
(D) Depalmitoylation activity analyzed by fluorogenic palmitoyl-transferase assay of 
bacterially expressed and purified APT1WT and APT1SA measured with increasing 
concentrations of Mu-6S-Palm-β-Glc substrate. n=3 replicates per condition. Results 
shown are from a representative trial from three independent experiments. (E) 
Depalmitoylation activity analyzed by fluorogenic palmitoyl-protein thioesterase assay of 
bacterially expressed and purified APT1WT and APT1SD measured with increasing 
concentrations of Mu-6S-Palm-β-Glc substrate. n=3 replicates per condition. Results 
shown are from a representative trial from three independent experiments. (F) WM239A 
cells expressing APT1WT or catalytically inactive mutant APT1S119A were treated with 
purified 150 ng/ml Wnt5a or control buffer for 15 minutes, APT1 was immunopurified 
using anti-FLAG magnetic particles, and depalmitoylation activity was measured by 
fluorogenic palmitoyl-protein thioesterase assay using 0.64 mM Mu-6S-Palm-β-Glc. (G) 
DPP-3 depalmitoylation assay using 5 µM of depalmitoylation probe DPP-3 in HEPES 
(20 mM, pH 7.4, 150mM NaCl, 0.1% Triton X-100) with either 50 nM purified APT1WT, 
APT1S209D or catalytically inactive APT1S119A and fluorescence emission was measured 
over time (λex490/9 nm;  λem 545/20 nm). Error bars indicate s.e.m., n=3 replicates per 
condition. Results shown are from a representative trial from three independent 
experiments. 
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DISCUSSION 
 The resorufin acetate hydrolysis assay had many pitfalls. The first being the use 
of the artificial substrate. We were afraid that we were not capturing the differences in 
catalytic activity between the mutants because the substrate utilized in this protocol was 
so unlike APT1’s typical substrates and very artificial compared to a palmitoylated 
substrate. After confirmation that there were significant differences among the mutants 
using the other two assays, we decided this assay was not accurately capturing the true 
enzymatic activity of APT1.  
Although the fluorogenic palmitoyl-palmitoylation assay with MU-6S-Palm-β-Glc 
utilized a substrate with a palmitate group, there proved to be many solubility issues that 
resulted in inconsistencies across repeated experiments. Furthermore, the additional 
reaction with β-glucosidase only added to those inconsistencies. Adding the extra layer 
of variability with β-glucosidase, we were unable to get consistent results and concluded 
this assay had too many variables and technical challenges. 
After careful interpretation of these assays, we concluded use of the DPPs was 
the most accurate way to capture APT1’s depalmitoylating activity. We go into detail 
about this experimental approach in the subsequent chapter, Chapter 3. We are able to 
use the DPP-3 substrate to study APT1’s depalmitoylating activity in real time, resolved 
any solubility issues because the synthesized probe was easy to dissolve and work with, 
and are able to use the probe in important live cell imaging experiments. Because of 
these consistent results and added benefits, we utilized this unique technique for our 
remaining studies in the subsequent chapters. 
 
METHODS 
Resorufin acetate assay 
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Protocol is adapted from Hwang, S., 2015. Resorufin acetate was added to 
immunopurified APT1 wild-type or APT1 phospho-mutants. Fluorescent product was 
measured by using Tecan plate reader with excitation and emission filters of λex 535(25) 
nm and λem 590(20) nm, respectively. 
Fluorogenic palmitoyl protein thioesterase assay with MU-6S-Palm-ß-Glc 
Protocol is adapted from Van Diggelen et al., 1999. 4-methylumbelliferyl 6 thio-palmitate-
ß-D-glucopyranoside (Mu-6S-Palm-β-Glc) (Santa Cruz Biotechnology, Dallas, TX). 
Bacterially expressed and purified APT1 or immunopurified APT1 (see methods below) 
was added to increasing concentrations of Mu-6S-Palm-β-Glc substrate solution 
containing 15 mM DTT, 0.375% Triton-X-100. After a 1-hour incubation at 37°C, 
samples were boiled to stop the APT1 reaction and then allowed to cool. Almond β-
glucosidase (Sigma) was added and the reaction mixture incubated again for 30 minutes 
at 37°C to hydrolyze the reaction intermediate MU-6-thio-β-glucoside. All enzymatic 
reactions were terminated by the addition of 200 µl of 0.5 M Na2CO3/NaHCO3 pH 10.7, 
containing 0.025% Triton-X-100 and then the fluorescence was measured using a Tecan 
plate reader at λ449 nm.  
Fluorogenic palmitoyl thioesterase assay with DPPs 
APT1 was assayed for depalmitoylating activity as described previously (Kathayat et al. 
2017). 
Purification of APT1 
Wild type and APT1 mutants (FLAG tagged) were cloned into the pET-28 plasmid 
backbone. Bacteria were grown overnight at 37°C in the presence of 100 µg/ml 
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ampicillin and 50 µg/ml chloramphenicol. Next, fresh LB or TB was inoculated with the 
overnight bacteria and grown for 4 hours at 37°C until OD600= 0.6-1.0. Expression of 
APT1 was induced with final concentration of 1 mM IPTG for 2 hours at 37°C or 
overnight at 18oC. Cells were pelleted at 8000 RPM for 15 minutes at 4°C. Pellet was 
resuspended in 50 mM HEPES pH 8.0, 300 mM NaCl, 1% Triton X-100, 20 mM 
Imidazole (Sigma), 1 mM Phenylmethylsulfonyl fluoride (PMSF), 1 mM dithiothreitol or 
25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 1mM PMSF, 10mM 2-
Mercaptoethanol, complete EDTA free protease inhibitor cocktail (Pierce). Lysate was 
sonicated at 50% duty cycle for 30 second pulses two times on ice or 50% duty cycle for 
30 pulses on and 30 pulses off for 30 minutes at 4oC. Lysate was centrifuged at 12,000 
RPM for 15 minutes at 4°C. Supernatant was incubated with Ni Sepharose 6 Fast Flow 
beads (GE Healthcare) at 4°C rocking for 3 hours or overnight. Beads were washed 
three times with wash buffer (50mM HEPES pH 8.0, 300mM NaCl, 40mM Imidazole) or 
500mL of wash buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 40 mM 
Imidazole, 10mM 2-Mercaptoethanol). Protein was eluted using 50 mM HEPES pH 8.0, 
300 mM NaCl, 250 mM Imidazole by rocking for 45 minutes at 4°C or 50mL of 25 mM 
HEPES pH 7.5, 500mM NaCl, 300mM Imidazole, 10mM 2-Mercaptoethanol at 4°C.   
Cell lines and culture conditions 
Metastatic melanoma cell line WM239A (BRAF V600D) (Wistar Institute) were cultured 
in RPMI 1640 medium (Gibco-BRL, Grand Island, NY) supplemented with 10% fetal 
bovine serum (FBS) (GE Life Sciences). Cell lines were authenticated routinely by short 
tandem repeat profiling by the Wistar Institute prior to use. 
Immunoprecipitation 
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WM239A cells ectopically expressing APT1-CFP-FLAG wild-type/mutants were treated 
with control buffer or 150 ng/ml Wnt5a for specified time period and then lysed in lysis 
buffer containing 1% Triton-X 100, 50 mM Tris pH 7.5, 150 mM NaCl supplemented with 
protease and phosphatase inhibitors (1µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml 
pepstatin A, 1mM PPi, 2nM NaVO4, 150mM NaF). Insoluble cell debris was removed by 
centrifugation (13,000 RPM for 10 min at 4°C. Lysate was incubated with FLAG M2 
magnetic beads (Sigma-Aldrich, St. Louis, MO) for 1.5 hours. Beads were washed with 
lysis buffer and protein was eluted using FLAG peptide for 1 hour at room temperature. 
Samples were separated by SDS-PAGE and transferred to either nitrocellulose 
membrane (Life Technologies, Thermo Fisher Scientific, Waltham, MA) for phospho-
APT1 antibody (YenZym Antibodies, San Francisco, CA) or PVDF membrane (Millipore, 
Burlington, MA) for all other antibodies used. 
Purification of recombinant Wnt5a and treatments with Wnt5a 
Wnt5a was purified from mouse L-cells overexpressing human Wnt5a as described 
previously (Willert et al., 2003). Control cells were treated with control buffer with 
identical detergent conditions as the Wnt5a purification buffer. 
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CHAPTER 3: WNT5A SIGNALING INDUCED PHOSPHORYLATION INCREASES 
APT1 ACTIVITY AND PROMOTES MELANOMA METASTATIC BEHAVIOR 
 
This chapter has been previously published in: 
Sadeghi, R. S., Kulej, K., Kathayat, R. S., Garcia, B. A., Dickinson, B. C., Brady, D. C., 
and Witze, E. S. (2018) Wnt5a signaling induced phosphorylation increases APT1 
activity and promotes melanoma metastatic behavior. eLife 7 
 
OVERVIEW 
 Many studies have reported a correlation between elevated Wnt5a expression 
and melanoma and observations of increased motility and invasion mediated by Wnt5a 
signaling but fail to define the mechanistic details of how Wnt5a signaling is mediating 
these effects. Prior to this publication, there was a gap in the literature addressing how 
Wnt5a signaling, specifically Wnt5a induced APT1-mediated depalmitoylation, is 
contributing to metastatic behavior in melanoma. We hypothesized APT1 activity and 
function was being regulated by Wnt5a signaling and aimed to determine the 
mechanism of APT1 regulation. Here, we define a phospho-switch on APT1 that 
increases APT1’s depalmitoylating activity, resulting in increased melanoma invasion, 
and decreased APT1 dimer formation.  
  
INTRODUCTION 
The Wnt5a signaling pathway plays a paramount role in important biological 
processes as it regulates cell polarity and polarized cell movement during embryonic 
development. Wnt5a expression is strongly correlated with melanoma progression and 
metastasis (Bitter et al., 2000, Carr et al., 2003). Melanoma is the deadliest form of skin 
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cancer, with a 5-year survival rate of only 17% for metastatic melanoma patients 
(Sandru et al., 2014). Previously, the elevated expression of Wnt5a in human melanoma 
samples and subsequent in vitro studies have suggested a role for Wnt5a in melanoma 
metastasis (Bitter et al., 2000, Carr et al., Forno et al.). Importantly, Wnt5a expression is 
positively correlated with poor outcome, with high Wnt5a expression being associated 
with decreased patient survival (Forno et al., 2008). With this information, it has been 
suggested that Wnt5a expression be used as a prognostic clinical risk factor (Forno et 
al., 2008). However, the exact mechanisms by which Wnt5a promotes metastatic 
behavior remains unknown. Thus, elucidation of the signaling events downstream of 
Wnt5a that promote polarized cell movement and metastatic behavior have the potential 
to enhance our understanding of the contribution of Wnt5a to melanoma metastasis. 
Our lab and others have shown Wnt5a signaling promotes migration and 
invasion in melanoma cells (Dissanayake et al., 2007, Wang et al., 2015, Weeraratna at 
al., 2002). Wnt5a is a secreted ligand in the noncanonical Wnt signaling pathway and 
upon interacting with its Frizzled receptor, activates a signal transduction cascade (Sato 
et al., 2010). Wnt5a signaling controls cell polarity and directional cell movement, and 
Wnt5a treatment promotes recruitment and reorganization of proteins involved in cell 
adhesion and cell signaling (Witze et al., 2008, Wang et al., 2015). Wnt5a stimulation 
promotes asymmetrical localization of cell adhesion molecules, increases cell motility, 
and elevates levels of free Ca2+ to induce Ca2+ signaling in a polarized manner (Witze et 
al., 2008, Witze et al., 2013). The tyrosine kinase receptor ROR2, which is 
predominantly expressed in metastatic melanoma, has been shown to specifically 
interact with Wnt5a and mediate Wnt5a signaling (O’Connell et al., 2010). In addition to 
reorganization of the actin cytoskeleton and polarized localization of cell adhesion 
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molecules, others have shown that elevated Wnt5a expression promotes melanoma 
invasion and human biopsies directly correlated Wnt5a expression with tumor grade 
(Weeraratna at al., 2002). 
Pro-metastatic cell adhesion molecules, such as transmembrane receptors CD44 
and MCAM (Melanoma Cell Adhesion Molecule), have been shown to play a role in cell 
migration and metastasis. CD44 levels are elevated in multiple cancer types and MCAM 
is expressed in melanoma cells and not untransformed melanocytes (Weilenga et al., 
1993, Shih et al., 1994a, Shih et al., 1994b). Palmitoylation of these cell adhesion 
molecules strongly influences protein function. CD44 has been shown to be 
palmitoylated and inhibiting CD44 palmitoylation through cysteine point mutations 
strongly enhanced breast cancer migration (Babina et al., 2014). Similarly, cysteine point 
mutations that block MCAM palmitoylation increases metastatic cell behavior in 
melanoma cells both in vitro and in vivo (Wang et al., 2015). 
S-Palmitoylation is the reversible addition of a 16-carbon fatty acid to cysteine 
residues via a thioester linkage. Palmitate addition is mediated by palmitoyl-transferases 
and acyl protein thioesterases (APTs) remove palmitate from proteins to regulate protein 
localization, trafficking, and cell signaling (Vartak et al., 2014, Linder and Deschenes et 
al., 2007, Lin and Conibear at al., 2015). Acyl protein thioesterases 1 and 2 (APT1 and 
APT2; aka LYPLA1 and LYPLA2) are cytosolic depalmitoylases that have been 
proposed to act constitutively to depalmitoylate proteins from membranes. However, 
there is evidence that protein depalmitoylation is a signal regulated modification. Wnt5a 
stimulation has been shown to induce the depalmitoylation of both MCAM and CD44 
through APT1 (Wang et al., 2015).  Wnt5a mediated melanoma cell invasion is reduced 
by treatment with a small molecule inhibitor of APT proteins. Another group has also 
27 
 
shown that growth factor stimulation is also sufficient to inhibit depalmitoylating activity of 
APT proteins (Kathayat et al., 2016). Wang, et al. demonstrated that increased APT1 
expression increased melanoma invasion in the absence of exogenous Wnt5a (Wang et 
al., 2015). It remains to be determined how Wnt5a signaling increases depalmitoylation 
through APT1. These results led us to investigate the link between Wnt5a signaling and 
regulation of APT1-mediated depalmitoylation. We hypothesized APT1 depalmitoylating 
activity could be regulated by upstream signaling events, specifically the Wnt5a signaling 
pathway. 
Here, we uncover a mechanism by which the non-canonical Wnt signaling 
pathway increases the depalmitoylating activity of APT1. We have mapped a regulatory 
phosphorylation site on APT1 and utilizing site specific point mutations, we unravel the 
impact of phosphorylation on APT1 activity and its importance in melanoma cell 
invasion. Using a depalmitoylation probe (DPP) that measures depalmitoylating activity 
(Kathayat at al., 2016, Qiu et al., 2017 and Beck et al., 2017), we show APT1 
phosphorylation increases its depalmitoylating activity. This is the first study showing a 
signaling pathway can direct protein depalmitoylation through a phospho-switch on 
APT1 that we propose functions to disrupt an inactive APT1 dimer. 
 
RESULTS 
Wnt5a Signaling Induces APT1 Phosphorylation 
Wnt5a induced metastatic cell behavior was previously shown to be dependent 
on increased protein depalmitoylation driven by APT1 (Wang et al., 2015). We 
hypothesized a mechanism for increased depalmitoylation could be a result of regulatory 
post-translational modifications of APT1 that increases APT1 activity. To investigate if 
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APT1 is post-translationally modified in response to Wnt5a stimulation, we used mass 
spectrometry to identify Wnt5a dependent post-translational modifications (PTMs) of 
APT1. Low Wnt5a producing WM239A melanoma cells expressing CFP-FLAG tagged 
wild type APT1 (APT1WT-CFP-FLAG) were treated with purified Wnt5a and APT1 was 
immunoprecipitated using anti-FLAG magnetic particles. APT1 was eluted with FLAG 
peptide. The immunopurified APT1 was alkylated and trypsinized and analyzed by mass 
spectrometry. The only phosphorylation sites identified on APT1 were on serine residues 
209 and 210. Whereas single phosphorylation of either serine 209 or 210 was detected, 
we can’t rule out the possibility of dual phosphorylation (Figure 3.1A and 3.1B). These 
findings are consistent with a previous high throughput mass spectrometry screen by 
another group that identified APT1 phosphorylation on serine residues 209 and 210 in 
laryngeal cancer cells (Phosphosite.org, site group ID: 25299324 and 25299327).  
We generated separate phospho-specific antibodies to phospho-site Ser209 and 
Ser210 of APT1 (YenZym Antibodies) to detect phosphorylated APT1 in melanoma cell 
lysates. To validate the antibodies, WM239A cells ectopically expressing APT1WT-CFP-
FLAG were treated with purified Wnt5a for 15 minutes. APT1WT-CFP-FLAG was then 
immunoprecipitated and separated by SDS-PAGE followed by immunoblotting. With 
phospho-APT1 antibodies to both serine 209 and serine 210, we detected 
phosphorylated APT1 (pS209-APT1/pS210-APT1) that increased following Wnt5a 
stimulation (Figure 3.1C). The induction of APT1 phosphorylation at Ser210 was 
detected in whole cell lysate without immunoprecipitation, showing a relatively high 
stoichiometry of phosphorylated APT1 to total APT1 after Wnt5a stimulation (Figure 
3.1D). We also observe a similar, but weaker, increase in exogenous phospho-APT1 in 
whole cell lysate utilizing the pS209-APT1 antibody in response to Wnt5a (data not 
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shown). However, we were unable to detect phosphorylation of the endogenous APT1 in 
the whole cell lysate from these cells (data not shown). To determine the temporal 
kinetics of Wnt5a induced APT1 phosphorylation, WM239A cells ectopically expressing 
APT1WT-CFP-FLAG were treated with purified Wnt5a for increasing lengths of time, 
APT1WT-CFP-FLAG was then immunoprecipitated and APT1 phosphorylation was 
measured by immunoblotting. APT1 phosphorylation peaked at 30 min and began to 
decrease at 60 min (Figure 3.1E). To determine the function of the Wnt5a induced 
phosphorylation, a phospho-deficient APT1 double mutant was generated by mutating 
both serine residues 209 and 210 to alanine (from here on referred to as APT1SA). When 
WM239A cells ectopically expressing APT1SA are treated with Wnt5a, the levels of 
phosphorylation of APT1 at Ser210 measured by immunoblotting were unchanged 
compared to cells expressing APT1WT (Figure 3.1F).  
The crystal structure of APT1 has been previously determined (Devedjiev et al., 
2000, Won at al., 2015) allowing us to model where the phosphorylated serine residues 
are positioned on the three-dimensional structure (PDB:5sym). We found that the 
phosphorylated serine residues 209 and 210 are solvent exposed on the lip of the 
hydrophobic putative acyl-binding channel and adjacent to the catalytic triad (Ser119, 
His208, Asp174), suggesting phosphorylation of these sites could influence APT1 
activity (Figure 3.1G). Together, these results indicate Wnt5a signaling in melanoma 
cells induces APT1 phosphorylation at serine residues 209 and 210 and our phospho-
specific antibodies are selective for these sites.  
APT1 Phosphorylation Increases Depalmitoylating Activity 
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To investigate how Wnt5a induced phosphorylation of APT1 affects its function, 
phosphorylated serine 209 was mutated to a negatively charged aspartic acid 
(APT1S209D) to mimic the negative charge of phosphate on serine 209. To measure APT1 
activity, we utilized a recently developed fluorescent depalmitoylation probe, DPP-3, that 
contains a thiol conjugated 7 carbon fatty acid that when hydrolyzed, generates a 
fluorescent product that can be measured at λex490/9 nm;  λem 545/20 nm (Kathayat et 
al. 2017). This probe served as a reporter to measure the depalmitoylating activity of 
APT1 and APT1 mutants both in vitro and in live cells. 6x His-tagged APT1 expressed 
and purified from E. coli was incubated with DPP-3 and the relative fluorescence was 
measured over time. APT1S209D was found to have increased depalmitoylating activity 
compared to APT1WT (Figure 3.2A). A catalytically inactive mutant where catalytic serine 
119 is mutated to alanine (referred to as APT1S119A) was used as a negative control and 
generated minimal fluorescence throughout the duration of the assay (Figure 3.2A). We 
next evaluated the depalmitoylating activity of APT1WT and APT1S209D using DPP-3 in the 
presence of increasing concentrations of DPP-3 substrate to determine the initial 
velocities at multiple substrate concentrations (Figure 3.2B and 3.2C). We measured 
higher initial velocities for APT1S209D at each substrate concentration compared to 
APT1WT (Table 1).  
To determine the effect of Wnt5a stimulation on APT1 depalmitoylating activity, 
WM239A cells were incubated with DPP-3 and fluorescence emission was measured at 
15, 30, and 45 minutes post Wnt5a treatment by live-cell microscopy (Figure 3.2 – figure 
supplement 1A). We quantified fluorescence emission in individual cells and determined 
that Wnt5a stimulation significantly increased the fluorescence emission compared to 
control buffer treated cells, indicating an increase in endogenous APT1 activity (Figure 
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3.2D). To confirm the increase in fluorescence emission in response to Wnt5a was 
through APT1, we immunoprecipitated APT1 from WM239A APT1WT cells stimulated 
with purified Wnt5a or untreated control cells, and measured depalmitoylating activity in 
vitro using DPP-3. APT1 isolated from Wnt5a stimulated cells showed an increase in 
depalmitoylating activity compared to untreated control (Figure 3.2 – figure supplement 
1B). While the non-canonical Wnt ligand Wnt5a is sufficient to increase APT1 activity we 
found stimulation with the canonical Wnt ligand, Wnt3a, was unable to increase APT1 
activity compared to Wnt5a and was similar to cells treated with control buffer (Figure 
3.2E). We confirmed these cells are competent to respond to the Wnt3a concentration 
used because we observe stabilization of β-catenin beginning at 75 ng/ml of Wnt3a 
(Figure 3.2 – figure supplement 1C). Therefore, the ability to increase APT1 activity 
appears to be specific to the non-canonical Wnt pathway.  
To directly assess how the phosphorylation state of APT1 affects 
depalmitoylation in live cells, WM239A melanoma cells expressing APT1WT or the 
phospho-mutants APT1SA and APT1S209D were incubated with the DPP-3 probe for 30 
minutes and fluorescence emission was measured by live-cell microscopy. Consistent 
with the in vitro results, APT1S209D has greater depalmitoylating activity in cells compared 
to either APT1WT or APT1SA (Figure 3.2F, Figure 3.2 – figure supplement 1D).  To 
determine the contribution of APT1 phosphorylation to the Wnt5a mediated increase in 
APT1 activity, we treated cells expressing either APT1WT, APT1SA, or APT1S209D with 
Wnt5a or control buffer and measured the APT1 activity with the DPP-3 probe. Wnt5a 
treatment increases APT1WT activity to levels higher than the phosphomimetic mutant 
APT1S209D. As expected Wnt5a stimulation is unable to increase activity of phospho-
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dead APT1SA or further increase the constitutive elevated activity of APT1S209D (Figure 
3.2F).  
To demonstrate that activity of a protein kinase is responsible for the Wnt5a-
mediated increase in APT1 activity, we treated cells with pan protein kinase inhibitors to 
block the Wnt5a mediated increase in APT1 activity. We pre-treated WM239A cells 
expressing APT1WT with either the serine/threonine kinase ATP-competitive inhibitor BI-
D1870 or the broad-spectrum kinase inhibitor staurosporine for 1 hour, incubated the 
cells with the DPP-3 probe, and measured fluorescence over time by live-cell 
microscopy during treatment with Wnt5a or control buffer. Treatment with either protein 
kinase inhibitors inhibited the Wnt5a mediated increase in APT1 activity to levels 
comparable to unstimulated cells (Figure 3.2G). Although the identity of the Wnt5a 
regulated kinase remains unknown, these results suggest that phosphorylation of APT1 
is a main driver of increased APT1 activity in response to Wnt5a. 
Expression of APT1S209D Decreases Levels of a Palmitoylated Protein Substrate 
We next asked if we could observe a similar phosphorylation dependent increase 
in depalmitoylating activity by measuring palmitoylation of a protein substrate in cells. 
The extent of protein palmitoylation is the result of an equilibrium between palmitoylation 
and depalmitoylation of substrates. To determine the immediate effect of expressing the 
phospho-mutant forms of APT1 on protein palmitoylation before the cell adapts and 
reaches a new steady state, we generated an inducible expression system to measure 
the effects of acute expression of APT1WT and the APT1 phosphorylation mutants on a 
specific depalmitoylation substrate. We chose MCAM (melanoma cell adhesion 
molecule), a known substrate of APT1 that is depalmitoylated in response to Wnt5a 
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stimulation, to investigate the contribution of APT1 phosphorylation on protein 
depalmitoylation (Wang et al., 2015). HEK 293T cells were co-transfected with a MCAM-
GFP plasmid and a doxycycline inducible plasmid containing FLAG-tagged APT1WT, 
APT1SA, or APT1S209D. Cells expressing APT1WT or mutants were induced with 
doxycycline for 15 hours. We found cells produced similar amounts of wild type and 
mutant APT1 protein (Figure 3.3A). The abundance of palmitoylated MCAM in each 
condition was then measured using the acyl biotin exchange assay (ABE). As a negative 
control, samples are processed without hydroxylamine (-HAM) leaving the palmitoylated 
cysteines intact and preventing biotin labeling. We found MCAM palmitoylation to be 
highest in APT1SA samples, indicating a decreased ability to depalmitoylate MCAM 
(Figure 3.3B). In contrast, the APT1S209D sample had the lowest level of palmitoylated 
MCAM, indicating the highest level of depalmitoylating activity. These results confirm the 
elevated depalmitoylating activity of APT1S209D we observe with the DPP-3 probe using a 
known palmitoylated protein in the cell. These data serve as evidence that the 
phosphorylation state of APT1 regulates depalmitoylation of endogenous substrates.  
APT1 Phosphorylation Increases Metastatic Behavior in Melanoma Cells 
Previous studies demonstrated increased APT1 expression results in increased 
invasion of melanoma cells embedded in collagen (Wang et al. 2015). To determine if 
this increased metastatic behavior was due to APT1 phosphorylation, we asked if 
APT1’s phosphorylation state affects melanoma invasion using the APT1 phospho-
mutants. Spheroids were formed from WM239A melanoma cells ectopically expressing 
CFP-FLAG-tagged APT1WT, APT1 SA, or APT1S209D, embedded in collagen, and the 
distance invaded was measured. We found that expression of APT1SA resulted in 
decreased invasion, similar to the negative control CFP, while APT1S209D significantly 
34 
 
increased melanoma invasion (Figure 3.3C and 3.3D). Since these melanoma cells are 
not Wnt5a treated, this dramatic increase in APT1S209D melanoma invasion is due to the 
single point mutation that mimics phosphorylation alone. When the activity of APT1 is 
inhibited with the selective inhibitor ML348, invasion is blocked, demonstrating the 
increased invasion observed in cells expressing APT1S209D is mediated by APT1 activity 
(Figure 3.3E). Together these results indicate phosphorylation of Ser209 increases 
depalmitoylating activity in cells, in turn increasing metastatic cell behavior. 
Phosphorylation Reduces APT1 Dimerization 
We next sought to determine how phosphorylation increases APT1 activity. We 
first asked if mutating the phospho-sites changed the thermostability of the protein using 
differential scanning fluorimetry of purified APT1WT, APT1SA, or APT1S209D mutants 
(Figure 3.4A). We found that each mutant possessed similar thermostability to that of 
APT1WT, indicating that the point mutations are not destabilizing the folding of the protein 
(Figure 3.4B). We next asked if the existing crystal structure might provide insight into 
the mechanism of APT1 activity. 
Previous crystal structures of APT1 revealed a weak asymmetric dimer in which 
the active site was occluded by the dimer interface, suggestive of an inactive dimer 
(Devedjiev et al., 2000, Won et al., 2015). Our interrogation of the crystal structure 
revealed that the phosphorylation sites 209 and 210 reside in the interface of the dimer 
and could potentially destabilize the dimeric form and decrease the inhibitory dimeric 
interaction. We measured the distance between the serine residues to the methionine 
(Met 65) residue on the opposite dimer and found a short distance of less than 4 Å 
(Figure 3.4C). We therefore hypothesized that phosphorylation of one of these sites 
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would be less favorable for dimer formation. Studies confirming the dimeric state of 
APT1 in solution are lacking. We therefore asked if we could detect dimeric APT1. We 
next sought to distinguish the APT1 monomer from the dimer by size-exclusion 
chromatography. When APT1 was loaded on the column at a concentration of 0.1 mg/ml 
both APT1WT and APT1S209D eluted at the same time as a 29kD standard. When the 
protein concentration is increased to 0.25 mg/ml a second peak of APT1WT begins to 
resolve closer to the 44kD standard (Figure 3.4D). When the APT1WT protein 
concentration was increased to 0.375 mg/ml a second peak was resolved near the 44kD 
standard that was not observed with APT1S209D. Additionally, the peak at 29kD for 
APT1WT is abolished at this concentration (Figure 3.4D). The identity of the protein in the 
shifted peak was confirmed as APT1 by visualizing the 25kD APT1 band by SDS-PAGE 
followed by Coomassie staining (Figure 3.4D). These results indicate APT1 does 
dimerize and phosphorylation of APT1 does not completely block dimerization but 
reduces the propensity for the dimer to form.  
Serine 210 is mutated in cancer and increases APT1 activity 
The APT1 gene is mutated in multiple tumor types, with the highest frequency of 
serine 210 mutated specifically to a leucine (Figure 3.5A) (Gao et al., 2013 & Cerami et 
al., 2012). To investigate if this mutation also increases APT1 activity, we mutated serine 
210 to leucine of APT1 (APT1S210L) and measured its depalmitoylating activity by 
incubating purified protein with the DPP-3 probe. After measuring fluorescence over 
time, we observed an increase in depalmitoylating activity of APT1S210L compared to 
APT1WT. When we compare the depalmitoylating activity of APT1S210L to APT1S209D, we 
find that S210L exhibits an almost identical increase in activity to the phospho-mimetic 
APT1S209D (Figure 3.5B). We also observe similar inhibition of APT1 depalmitoylation by 
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ML348 using the DPP-3 probe as a substrate for APT1S209D and APT1S210L (Figure 3.5 – 
figure supplement 1A). These results demonstrate that the high activity of the APT1 
phospho-mutants are still inhibited with ML348. To visualize how a S210L mutation 
would affect dimerization, we modeled the substitution on the three-dimensional crystal 
structure and determined a leucine at position 210 is located 5.5 Å from the methionine 
of the adjacent APT1 monomer (Figure 3.5C). With a neutral charge leucine positioned a 
small distance from the dimer interface, we propose steric hindrance disrupts the 
dimerization of APT1. 
We next asked if this mutation would also enhance the ability of APT1 to promote 
cell invasion, similar to what we observe in APT1S209D. To test the APT1S210L mutant’s 
effect on cell behavior, we generated spheroids from WM239A melanoma cell 
expressing CFP-FLAG-tagged APT1WT and APT1S210L, embedded them in collagen, and 
measured cell invasion each day over the course of 9 days. Expression of APT1S210L 
increased melanoma invasion when compared to APT1WT and negative control CFP 
(Figure 3.5D, Figure 3.5 – figure supplement 1B). Similar to the phospho-mimetic 
APT1S209D, treating spheroids expressing APT1S210L with ML348 significantly reduces cell 
invasion (Figure 3.5 – figure supplement 1C). These results demonstrate that APT1S210L 
increases metastatic behavior compared to wild type and this is dependent on the 
catalytic activity of APT1.  
In patients, increased Wnt5a expression is known to correlate with increased 
tumor grade and metastasis. To investigate if phospho-APT1 levels were also elevated 
in human melanoma samples and to establish human disease relevance, we stained 
human melanoma tumor arrays with our phospho-antibody (anti-pS209-APT1) and for 
total APT1 (anti-APT1 antibody). We discovered a correlation between high pAPT1 
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staining and increased tumor grade (Figure 3.5E). When looking at melanoma 
metastatic samples we observed the same correlation (Figure 3.5F, Figure 3.5 – figure 
supplement 1D), implicating increased APT1 phosphorylation with increased tumor 
progression and metastasis.  
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FIGURES 
Figure 3.1. Wnt5a signaling induces APT1 phosphorylation on serines 209 and 210. (A) 
Annotated MS/MS spectrum of identified S209 phosphopeptide of protein APT1. The 
image represents the observed fragment ions collected using MS/MS (HCD). Colored 
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lines represent matches between observed and expected fragment ions of the given 
peptides. Specifically, blue lines represent matches with y-type fragments, red lines with 
b-type fragments, and purple lines show immonium ions. (B) Annotated MS/MS 
spectrum of identified S210 phosphopeptide of protein APT1, as described in A. (C) 
APT1WT-CFP-FLAG was immunoprecipitated from lysates prepared from WM239A 
melanoma cells expressing APT1WT-CFP-FLAG treated with control buffer or 150 ng/ml 
of purified Wnt5a for 15 minutes and analyzed by SDS-PAGE followed by 
immunoblotting to detect phosphorylated APT1 using antibodies to pS209-APT1 and 
pS210-APT1. (D) Western blot of whole cell lysate (WCL) from WM239A cells 
expressing APT1WT-CFP-FLAG treated with control buffer or 150 ng/ml of Wnt5a for 15 
minutes. (E) WM239A cells expressing APT1WT-CFP-FLAG were treated with control 
buffer or 150 ng/ml of Wnt5a for increasing lengths of time and then APT1WT-CFP-FLAG 
was immunoprecipitated and analyzed by SDS-PAGE and immunoblotting to detect 
phosphorylated APT1 with anti-pS210-APT1 antibody. (F) WM239A cells expressing 
APT1WT-CFP-FLAG (WT) or APT1SA -CFP-FLAG (SA) were treated with control buffer or 
150 ng/ml of Wnt5a for 15 minutes. APT1 was immunoprecipitated and analyzed by 
SDS-PAGE and immunoblotting to detect phosphorylated APT1 with anti-pS209-APT1 
antibodies. (G) Three-dimensional model of APT1, showing the positions of Ser209 and 
Ser210 (magenta) adjacent to the catalytic residues Ser119, Asp174 and His208 (cyan). 
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Figure 3.2. Wnt5a stimulation increases APT1 depalmitoylating activity. (A) In vitro 
fluorescence assay using 5 µM of depalmitoylation probe DPP-3 in HEPES (20 mM, pH 
7.4, 150mM NaCl, 0.1% Triton X-100) with either 50 nM purified APT1WT, APT1S209D or 
catalytically inactive APT1S119A and fluorescence emission was measured over time 
(λex490/9 nm;  λem 545/20 nm). Error bars indicate s.e.m., n=3 replicates per condition. 
Results shown are from a representative trial from three independent experiments. (B) 
Linear regression of APT1WT (WT) enzymatic activity measured by fluorescence 
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emission of increasing DPP-3 substrate concentrations over time. Results are averaged 
from six independent experiments. (C) Linear regression of APT1S209D (SD) enzymatic 
activity measured by fluorescence emission of increasing DPP-3 substrate 
concentrations over time. Results are averaged from 6 independent runs. (D) 
Quantification of relative fluorescence of WM239A cells treated with control buffer or 150 
ng/ml of Wnt5a, loaded with 10 µM DPP-3, and then analyzed by live-cell fluorescence 
microscopy over time. Error bars indicate s.d., n=25 cells per condition, ****p<0.0001 by 
unpaired t-test analysis. Results shown are from three experiments. (E) Quantification of 
relative fluorescence of WM239A cells expressing APT1WT treated with control buffer, 
150 ng/ml of Wnt5a, or 150 ng/ml of Wnt3a, loaded with 5 µM DPP-3, and then analyzed 
by live-cell fluorescence microscopy after 30 minutes. Error bars indicate s.d., n=25 cells 
per condition, ****p<0.0001 by unpaired t-test analysis. Results shown are from three 
experiments. (F) Quantification of relative fluorescence generated by WM239A cells 
expressing either APT1WT (WT), APT1SA (SA), or APT1S209D (SD) treated with control 
buffer or 150 ng/ml Wnt5a, loaded with 10 µM DPP-3, and then analyzed by live-cell 
fluorescence microscopy after 30 minutes. Error bars indicate s.d., n=17-32 cells per 
condition, ****p<0.0001 by unpaired t-test analysis. Results shown are from three 
experiments. (G) Quantification of relative fluorescence of WM239A APT1WT cells 
treated with kinases inhibitors 10 µM BI-D1870, or 0.2 µM staurosporine or DMSO 
control for 1 hour, loaded with 10 µM DPP-3, treated with Wnt5a, and analyzed by live-
cell fluorescence microscopy after 30 minutes. Error bars indicate s.d., n=25 cells per 
condition, ****p<0.0001 by unpaired t-test analysis. Results shown are from three 
experiments. Quantification for all live-cell microscopy was determined by measuring the 
mean intensity of relative fluorescence for region of interests (background fluorescence 
was subtracted from mean intensity). 
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Figure 3.2 – figure supplement 1. Activity of APT1 in response to Wnt5a stimulation or 
the phosphomimetic mutation. (A) Representative images of WM239A cells loaded with 
10 µM DPP-3, treated with control buffer or 150 ng/ml Wnt5a, and then analyzed by live-
cell fluorescence microscopy at 15 minutes, 30 minutes, and 45 minutes, quantified in 
Figure 2D. (B) APT1WT was immunoprecipitated from WM239A whole cell lysate pre-
treated with control buffer or 150 ng/ml Wnt5a and analyzed by in vitro fluorescence 
assay. *p <0.05 by unpaired t-test analysis of – Wnt5a and + Wnt5a groups. (C) 
WM239A APT1WT cells were treated with control buffer, 75 ng/ml, or 150 ng/ml of 
recombinant Wnt3a for 1 hour, lysate was harvested and analyzed by SDS-PAGE to 
determine β-catenin stabilization. (D) Top panel: Representative images of APT1WT, 
APT1SA and APT1S209D WM239A cells treated with 10 µM of DPP-3 for 15 minutes, and 
then analyzed by live-cell microscopy. Bottom panel: Quantification of relative 
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fluorescence of WM239A APT1WT (WT), APT1SA (SA), and APT1S209D (SD) cells treated 
with control buffer or 150 ng/ml Wnt5a, loaded with 10 µM DPP-3, and then analyzed by 
live-cell fluorescence microscopy after 30 minutes. Error bars indicate s.d., n=17-32 cells 
per condition, ****p<0.0001 by unpaired t-test analysis. 
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Table 1. Enzyme kinetics of APT1WT and APT1S209D. Table of initial velocities (V0) of 
APT1WT and APT1S209D. Values were determined by incubating purified APT1WT and 
APT1S209D with increasing concentrations of DPP-3 substrates and measuring 
fluorescence for 240 seconds. The initial velocity of the reactions for APT1WT and 
APT1S209D activity was calculated by fitting the linear regression of the fluorescence vs. 
time. Results are averaged from six independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Substrate APT1
WT
APT1
SD
0.25μM 0.2012 ± 0.008627 0.4704 ± 0.01765
0.5μM 0.2316 ± 0.02656 0.8083 ± 0.03173
1.0μM 0.5496 ± 0.01478 1.612 ± 0.04416
5.0μM 0.6573 ± 0.03547 4.627 ± 0.2237
Fluoresence/Time (V0)
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Figure 3.3. APT1 phosphorylation increases APT1 depalmitoylating activity in cells and 
increases melanoma invasion. (A) HEK 293T cells transfected with constitutively 
transcribed MCAM-GFP and doxycycline inducible APT1WT-FLAG (WT), APT1SA-FLAG 
(SA), or APT1S209D-FLAG (SD). After 15 hours of induction with 1 µg/ml doxycycline, 
APT1 protein expression was determined by immunoblotting with anti-GFP (MCAM-
GFP) and anti-FLAG (APT1-FLAG) antibodies. (B) An acyl-biotin exchange (ABE) assay 
was used to measure MCAM palmitoylation in cell lysates from cell lines described in 
(A). In the ABE assay addition of hydroxylamine (+HAM) removes palmitate from 
cysteine residues that are then conjugated to biotin-HPDP. Biotinylated proteins are then 
isolated on streptavidin beads and palmitoylated proteins are analyzed by SDS-PAGE 
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followed by immunoblotting. Hydroxylamine is withheld as a negative control (-HAM) 
MCAM-GFP is detected with anti-GFP antibodies and APT1-FLAG is detected with anti-
FLAG antibodies. Results shown are a representative trial from three independent 
experiments. (C) WM239A melanoma cells expressing APT1WT (WT), APT1SA (SA), or 
APT1S209D (SD) were grown on agarose to form spheroids that were embedded in 
collagen and images were taken on day 7 and the distance invaded was measured. 
Representative images from day 7 are shown. (D) Quantification of WM239A spheroid 
invasion assay in (C). Error bars indicate s.e.m., n=14-34 spheroids counted per 
condition, ****p<0.0001 by unpaired t-test analysis. Results shown are from four 
experiments. (E) Quantification of WM239A spheroid invasion assay of APT1S209D (SD) 
treated with DSMO control or 10 µM ML348, every other day for 7 days and distance 
invaded measured at day 7. Error bars indicate s.e.m., n=6 spheroids counted per 
condition, **p=0.0017 by unpaired t-test analysis. Results shown are a representative 
trial from three independent experiments. 
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Figure 3.4. APT1 phosphorylation impedes dimer formation. (A) Differential scanning 
fluorimetry (DSF) of purified APT1WT, APT1SA and APT1S209D. (B) Melting curves of 
purified APT1WT, APT1SA and APT1S209D as determined by DSF. Results shown from 
DSF analysis are a representative trial from three independent experiments. (C) Top 
panel: Three-dimensional model of crystal structure of APT1 dimer interface. Ser209 and 
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Ser210 (pink) are located 4.3 Å away from Met65 (blue) of the adjacent APT1 monomer. 
Catalytic triad Ser119, Asp174 and His208 are highlighted (cyan). Bottom panel: Zoom 
in of APT1 dimer interface. (D) Top panels: Chromatogram of purified APT1WT (cyan) 
and APT1S209D (magenta) from size-exclusion chromatography at three protein 
concentrations. Bottom panel: SDS-PAGE followed by Coomassie staining of eluted 
fractions after separation by size-exclusion chromatography of APT1WT and APT1S209D. 
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Figure 3.5. Increased phospho-APT1 staining correlates with increased tumor grade 
and metastasis. (A) Schematic of APT1 mutations from human tumor samples. Adapted 
from results generated using cBioPortal (Gao et al., 2013; Cerami et al., 2012). (B) In 
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vitro fluorescence assays of 5 µM of DPP-3 with either 50 nM purified APT1WT, 
APT1S210L APT1S209D, or catalytically inactive APT1S119A and fluorescence emission was 
measured (λex490/9 nm;  λem 545/20 nm). Error bars indicate s.e.m., n=3 replicates per 
condition. Results shown are a representative trial from three independent experiments. 
(C) Three-dimensional model of crystal structure of APT1 dimer interface with Ser210 to 
Leu mutation. Ser210Leu (pink) is located 5.5 Å away from Met65 (blue) of the adjacent 
APT1 monomer. Catalytic triad Ser119, Asp174 and His208 are shown in cyan. (D) 
Quantification of WM239A CFP-FLAG (CFP), APT1WT-CFP-FLAG (WT), and APT1S210L-
CFP-FLAG (S210L) spheroids embedded in collagen and distance invaded measured at 
day 8. Error bars indicate s.e.m., n=8 spheroids per condition, *p=0.0150 by unpaired t-
test analysis. Results shown are from three independent experiments. (E) 
Immunohistochemistry staining of melanoma tumors in a human melanoma tumor array 
using pS209-APT1 and APT1 antibodies. (F) Immunohistochemistry staining of 
metastatic tumor samples in a human melanoma tumor array using anti-pS209-APT1.  
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Figure 3.5 – figure supplement 1. Response of APT1S210L mutant to APT1 inhibitor 
ML348. (A) Quantification of fluorescence response of 5 µM DPP-3 treated with either 
50 nM purified APT1 (APT1WT, APT1S209D, APT1S210L, or catalytically inactive APT1S119A) 
for 30 min each in the presence or absence of 50 µM ML348 (λex490/9 nm;  λem 545/20 
nm). Error bars indicate s.d., n=3 replicates per condition. Results shown are a 
representative trial from three experiments. (B) Representative images of APT1WT and 
APT1S210L collagen invasion assay in Figure 5D. Images are of spheroids on day 8 (D8). 
Scale bar = 500 µm. (C) Quantification of WM239A spheroid invasion assay of APT1S210L 
(SL) treated with DSMO control or 10 µM ML348 every other day for 7 days and distance 
invaded measured on day 7. Error bars indicate s.e.m., n=5-6 spheroids per condition, 
****p<0.0001 by unpaired t-test analysis. Results are from three independent 
experiments. (D) Immunohistochemistry staining of metastatic tumors in a human 
melanoma tumor array using anti-APT1 antibodies. 
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DISCUSSION 
Protein palmitoylation is often considered a constitutive modification required for 
correct protein localization and function. Here, we uncover a molecular switch that 
promotes protein depalmitoylation in response to non-canonical Wnt signaling. We 
demonstrate Wnt5a signaling induces APT1 phosphorylation and this activates APT1, 
increasing its depalmitoylating activity and thus depalmitoylation of its substrates. While 
phosphorylation of these serine residues has been observed in mass spectrometry 
studies, this is the first example of differential phosphorylation of APT1 in response to an 
extracellular signal. Ultimately, activation of APT1 signaling results in increased 
depalmitoylating activity, leading to increased melanoma invasion, and correlating with 
increased tumor grade and metastasis. 
 Understanding APT1 protein function has been hindered by a deficiency in 
assays for measuring thioesterase activity either in vitro or in cells. Here, we take 
advantage of a recently developed small molecule fluorophore, DPP-3, which allowed us 
to measure the activity of APT1 both in vitro and in cultured cells. This assay revealed 
the phospho-mimetic mutant APT1 has greater thioesterase activity compared to wild-
type APT1. The increase in activity was also observed by live cell imaging and the 
phospho-dead mutant had similar activity to wild-type APT1. Using live imaging, we were 
able to demonstrate that the ability to increase endogenous APT1 activity is specific to 
Wnt5a and the noncanonical Wnt pathway, as we found Wnt3a lacks this ability. 
 The first crystal structure of APT1 revealed a dimer with the active site buried in 
the dimer interface (Devedjiev et al., 2000), suggesting the dimer must dissociate prior to 
interaction with its substrate. The phosphorylation sites are located on the edge of the 
hydrophobic channel distant from the site of catalysis but at the dimer interface. Our 
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proposed model is phosphorylation impedes the formation of an inactive dimer. Few 
studies have examined if APT1 forms a dimer in solution. Using both size-exclusion 
chromatography and chemical crosslinking, we find evidence of dimeric APT1 in 
solution. When measured by crosslinking, the phospho-mimetic mutation decreases but 
does not eliminate the dimeric pool of APT1. However, size-exclusion chromatography 
detected a complete shift of the APT1WT monomer population to the dimer. The shift was 
dependent on the concentration of APT1 since at the APT1WT dimer concentration 
APT1S209D remains a monomer. Furthermore, using three-dimensional modeling, we 
were able to determine the distance between the serine’s that are phosphorylated and 
the neighboring APT1 in the dimer interface to be 4.3 Å. With such a short distance 
between the serine and the adjacent APT1, it is consistent with the idea that 
phosphorylation of this serine would impede the dimerization of APT1. However, it is still 
unclear if this reduction in dimer formation is sufficient to account for the increase in 
APT1 activity. We still don’t know if the higher activity of APT1S209D compared to APT1WT 
is caused by reduced dimer formation or a conformational change in the protein that 
increases activity. Alternatively, phosphorylation could alter the conformation of APT1 
allowing it to accommodate the lipid substrate or increase the rate of catalysis 
independent of dimer formation.  
 When analyzing the results of the in vitro fluorogenic palmitoylation assay using 
the DPP-3 probe and the acyl-biotin exchange assay measuring palmitoylation of MCAM 
as a protein substrate, there is a small discrepancy between the two assays for 
phospho-deficient mutant APT1SA. In the acyl-biotin exchange assay, we observe 
APT1SA displaying decreased activity compared to APT1WT cells. Whereas in our in vitro 
depalmitoylation assay with the DPP-3 probe, we do not observe a significant difference 
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between the APT1SA mutant and APT1WT. It is important to note that in whole cells there 
are other factors that play a role in this signaling pathway and this might contribute to the 
difference in the acyl-biotin exchange assay, where we are measuring depalmitoylation 
of a protein APT1 substrate in this signaling pathway. It is possible that modifications of 
the substrate MCAM affect how its accessed or preference for depalmitoylation. Adaptor 
proteins may hinder or ease the depalmitoylation of the protein. Due to decreased 
melanoma invasion in collagen observed in APT1SA expressing cells, we hypothesize 
that the decreased depalmitoylation of MCAM may play a role in the APT1 mediated 
invasion. Thus, this is a more physiologically relevant measure of the depalmitoylation 
activity than solely using the artificial probe in vitro. Concerning the DPP-3 probe, it is 
still a reliable tool to assess APT1 depalmitoylation, when taken together with other data, 
which we have been able to do in this study.  
 The APT1 gene, LYPLA1, is amplified across a wide variety of tumor types, 
including 31.8%, 23.2%, and 13.8%, in neuroendocrine prostate cancer, uterine 
carcinosarcoma, and invasive breast carcinoma, respectively. Other cancers with 
amplified LYPLA1 include metastatic prostate adenocarcinoma, ovarian serous 
cystadenocarcinoma, and uveal melanoma (Beltran et al., 2016, Getz et al., 2013, and 
Eirew et al., 2015). Serine 210 is mutated not only in melanoma (Krauthammer et al., 
2012) but also in multiple tumor types including colorectal adenocarcinoma and lung 
squamous cell carcinoma (Giannakis, et al., 2016, Hammerman et al., 2012, Campbell 
et al., 2016). This bulky residue behaves similarly to the phosphorylated APT1 in vitro, 
suggesting this disease relevant mutation might result in increased depalmitoylation and 
thus increased invasion in patients. Using three-dimensional modeling, we find the 
leucine to be positioned 5.5 Å next the dimer interface and based on modeling, this 
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mutation will not accommodate dimeric conformation. Due to this finding, this signaling 
pathway becomes increasingly important, not only in Wnt5a driven cancers mentioned 
above but also for patients who present with APT1 mutations in other tumor types. There 
is a possibility an APT1 mutation in this phospho-site could be regulating cancer 
metastasis across other tumor types. Not surprisingly, the S210L mutation in APT1 is 
observed at a much lower frequency compared to well-established oncogenes frequently 
mutated in melanoma, such as BRAF or NRAS. We, therefore, think it is unlikely APT1 
mutations contribute significantly to oncogenesis and tumor initiation. We did map the 
positions in the three-dimensional structure of the other mutations in APT1 cataloged in 
the TCGA database (Figure 5A). The only mutation that is positioned within the dimer 
interface is S210L, making it unlikely that the other low-frequency mutations would 
increase APT1 activity through reduced dimerization. Therefore, APT1S210L may provide 
some selective advantage to tumor growth in vivo since it occurs at a higher frequency 
than the other mutations in APT1. 
The data we present offers insights into the Wnt5a signaling pathway and its 
contribution to tumor progression and metastasis. Patients who present with elevated 
Wnt5a expression are in dire need of effective therapy and directly targeting the Wnt5a 
pathway is one possible avenue (Prasad et al., 2015). By identifying increased APT1 
activity through either gene amplification or mutation of serine 210 as a driver of this 
pathway, we could expand the number of patients who can benefit from inhibition of the 
Wnt5a-APT1 pathway. This suggests APT1 signaling may play a larger role as a 
possible target for treating metastatic melanoma patients, especially those with APT1 
amplification/mutations or disease recurrence after other treatments.  
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Here we show regulation of protein depalmitoylation by activation of the Wnt5a 
signaling pathway. This novel discovery allows us to better understand how secreted 
signals regulate protein function and polarized cell behavior. Wnt5a signaling directly 
regulates APT1 depalmitoylating activity and protein function, with activation or 
mutations in this pathway contributing to their metastatic behavior. Novel therapeutics for 
Wnt5a driven cancers are lacking in the clinic. Understanding the signaling mechanism 
behind Wnt5a driven tumor progression and metastasis is imperative if we aim to create 
novel therapies against this pathway and to achieve our goal of increasing cancer 
patient survival. 
 
METHODS 
Purification of recombinant Wnt5a and treatments with Wnt5a and Wnt3a 
Wnt5a was purified from mouse L-cells overexpressing human Wnt5a as described 
previously (Willert et al., 2003). Control cells were treated with control buffer with 
identical detergent conditions as the Wnt5a purification buffer. For experiments utilizing 
Wnt3a treatment, cells were treated with recombinant Wnt3a (R&D Systems, 
Minneapolis, MN) for 1 hour at 37 °C before lysate was harvested as described.  
Cell lines and culture conditions 
Metastatic melanoma cell line WM239A (BRAF V600D) (Wistar Institute) were cultured 
in RPMI 1640 medium (Gibco-BRL, Grand Island, NY) supplemented with 10% fetal 
bovine serum (FBS) (GE Life Sciences). Cell lines were authenticated routinely by short 
tandem repeat profiling by the Wistar Institute prior to use. 
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Mass spectrometry analysis of APT1 phosphorylation sites 
All chemicals used for preparation of mass spectrometry samples were of at least 
sequencing grade and purchased from Sigma-Aldrich (St Louis, MO), unless otherwise 
stated. The 1% TritonX-100 detergent was removed from samples prior MS analysis by 
precipitation using chloroform (CHCl3)-methanol (MeOH) precipitation [Wessel et al.]. 
The protein pellet from CHCl3-MeOH precipitation was resuspended in 6 M urea/2 M 
thiourea in 50 mM ammonium bicarbonate, pH 8.3 supplemented with Phosphatase and 
Protease Inhibitors Mix (Thermo Fisher Scientific, Waltham, MA). Samples were reduced 
with 10mM DTT for 1 hour at room temperature and the carbamidomethylated with 20 
mM iodoacetamide (IAA) for 30 minutes at room temperature in the dark. After alkylation 
proteins were digested first with endopeptidase Lys-C (Wako, Cambridge, MA; MS 
grade) for 3 hours, after which the solution was diluted 10 times with 20 mM ammonium 
bicarbonate, pH 8.3. Subsequently, samples were digested with trypsin (Promega, 
Madison, WI) at an enzyme to substrate ratio of approximately 1:50 for 12 hours at room 
temperature. After digestion, the samples were concentrated to the volume of ∼100 μl by 
lyophilization. Phosphopeptide enrichment using titanium dioxide (TiO2) 
chromatographic resin was performed as previously described [Thingholm et al., 
Enghold et al.]. The lyophilized phosphorylated peptide samples were reconstituted in 
0.1% trifluoroacetic acid (TFA) and desalted using Poros Oligo R3 RP (PerSeptive 
Biosystems, Framingham, MA) P200 columns. The peptide samples were subsequently 
lyophilized and stored at −80 °C for further analysis. 
Dried samples were resuspended in buffer-A (0.1% formic acid) and loaded onto an 
Easy-nLC system (Thermo Fisher Scientific, San Jose, CA), coupled online with an 
Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific, San Jose, CA). 
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Peptides were loaded into a picofrit 25 cm long fused silica capillary column (75 μm 
inner diameter) packed in-house with reversed-phase Repro-Sil Pur C18-AQ 3 μm resin. 
The gradient length was 75 min. The gradient was from 2–26% buffer-B (100% 
ACN/0.1% formic acid) at a flow rate of 300 nl/min. The MS method was set up in a 
data-dependent acquisition (DDA) mode. For full MS scan, the mass range of 350–1200 
m/z was analyzed in the Orbitrap at 120,000 FWHM (200 m/z) resolution and 5 × 10e5 
AGC target value. HCD (higher energy collision dissociation) collision energy was set to 
32, AGC target to 10e4 and maximum injection time to 200 msec. Detection of MS/MS 
fragment ions was performed in the ion trap in the rapid mode using the TopSpeed 
mode (2 s). 
Raw MS-files were analyzed using Proteome Discoverer (v2.1, Thermo Scientific, 
Bremen, Germany). MS/MS spectra were converted to mgf files and searched against 
the UniProt-Human LYPLA1 (APT1) database (version June 2017) using SequestHT. 
Database searching was performed with the following parameters: precursor mass 
tolerance 10 ppm; MS/MS mass tolerance 0.6 Da; enzyme trypsin (Promega), with two 
missed cleavages allowed; fixed modification was cysteine carbamidomethylation; 
variable modifications were methionine oxidation, serine/threonine/tyrosine 
phosphorylation, asparagine and glutamine deamidation. Peptides were filtered for <1% 
false discovery rate, Sequest ion score >0.9. All MS-APT1 raw files have been deposited 
in the CHORUS database under project number 1456 (https://chorusproject.org/). 
Structural modeling 
Modeling of catalytic triad (serine 119, aspartate 174, and histidine 208) and serine 
residues 209 and 210 identified to be phosphorylated by MS analysis was performed in 
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MacPyMOL with the three-dimensional co-crystal structure of human APT1 in complex 
with an isoform selective inhibitor, ML348 at 1.55 A ̊ (PDB 5SYM). Modeling of the 
distance between the distance between the oxygen side chain of the serine residues 209 
and 210 in monomer A and the thiol group of methionine 65 in monomer B was 
performed in MacPyMOL with the three-dimensional co-crystal structure of human APT1 
in complex with an isoform selective inhibitor, ML348 at 1.55 A ̊ (PDB 5SYM). Modeling 
of serine 210 to leucine mutation identified in several cancers and the distance between 
the leucine backbone in monomer A and the thiol group of methionine 65 in monomer B 
was performed in MacPyMOL with the three-dimensional co-crystal structure of human 
APT1 in complex with an isoform selective inhibitor, ML348 at 1.55 A  ̊(PDB 5SYM). 
Immunoprecipitation 
WM239A cells ectopically expressing APT1-CFP-FLAG mutants were treated with 
control buffer or 150 ng/ml Wnt5a for specified time period and then lysed in lysis buffer 
containing 1% Triton-X 100, 50 mM Tris pH 7.5, 150 mM NaCl supplemented with 
protease and phosphatase inhibitors (1µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml 
pepstatin A, 1mM PPi, 2nM NaVO4, 150mM NaF). Insoluble cell debris was removed by 
centrifugation (13,000 RPM for 10 min at 4°C. Lysate was incubated with FLAG M2 
magnetic beads (Sigma-Aldrich, St. Louis, MO) for 1.5 hours. Beads were washed with 
lysis buffer and protein was eluted using FLAG peptide for 1 hour at room temperature. 
Samples were separated by SDS-PAGE and transferred to either nitrocellulose 
membrane (Life Technologies, Thermo Fisher Scientific, Waltham, MA) for phospho-
APT1 antibody (YenZym Antibodies, San Francisco, CA) or PVDF membrane (Millipore, 
Burlington, MA) for all other antibodies used. 
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Western blot analysis and antibodies 
Cells were harvested and lysed in 1% Triton X-100, 50mM Tris pH 7.5, 150mM NaCl 
supplemented with protease and phosphatase inhibitors (1µg/ml leupeptin, 1µg/ml 
aprotinin, 2µg/ml pepstatin A, 1mM PPi, 2nM NaVO4, 150mM NaF). Insoluble cell debris 
was removed by centrifugation (13,000 RPM for 10 min at 4°C. The protein 
concentration was determined by DC Protein method (BioRad, Hercules, CA). Equal 
amounts of total protein were separated by SDS-PAGE and transferred to either 
nitrocellulose membrane (Life Technologies, Thermo Fisher Scientific, Waltham, MA) for 
phosphor-APT1 antibody or PVDF membrane (Millipore, Burlington, MA) for all other 
antibodies used. The nitrocellulose membranes were blocked with 5% bovine serum 
albumin (BSA) in TBST (TBS, 0.1% Tween). The PVDF membranes were blocked with 
5% dry milk in TBST. All membranes were immunoblotted with different antibodies 
diluted in 5% BSA in TBST.  
The rabbit anti-human APT1 antibody (Abcam, Cambridge, MA) was used at 1:1000. 
The rabbit anti-human beta-actin (Cell Signaling Technologies, Danvers, MA) was used 
at 1:5000. The mouse anti-human MCAM antibody (Santa Cruz Biotechnology, Dallas, 
TX) was used at 1:1000. The secondary antibodies were HRP-conjugated 1:10000 
diluted in 5% BSA in TBST. Membranes were washed three times with TBST between 
the different steps.  
Spheroid Assay 
96-well plates were coated with 50 µl per well of sterile 1.5% noble agar and solidified at 
room temperature for 10 min. 200 µl of 2.5 × 104 cells/ml cell suspension was added to 
each well. Spheroids formed at 37°C and at 4% CO2 for 48 h. Collagen matrices were 
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prepared on ice using Pur Col purified bovine collagen (Advanced Biomatrix, Carlsbad, 
CA), Hyclone RPMI 1640 (5X) with sodium biocarbonate diluted to 1X in total volume 
and 10% FBS. Sterile NaOH was added to correct the collagen pH. 75 µl of collagen 
matrix was added to new wells and allowed to solidify at 37°C for 1 h. Spheroids were 
resuspended in 125 µl of collagen matrix and transferred to wells containing 75 µl of 
collagen. After collagen solidified at 37°C, 100 µl of fresh medium was added on top of 
the collagen. Medium was changed every other day. Images were taken every 24 h for 1 
– 10 days. For the invasion assays including ML348 and LGK-974: 10µM of ML348 
(Sigma-Aldrich, St. Louis, MO) was added to fresh media on the spheroids and changed 
every other day. 
Acyl-biotin exchange assay 
The ABE assay was performed as described (Wan et al., 2007). 
Purification of APT1 
Wild type and APT1 mutants (FLAG tagged) were cloned into the pET-28 plasmid 
backbone. Bacteria were grown overnight at 37°C in the presence of 100 µg/ml 
ampicillin and 50 µg/ml chloramphenicol. Next, fresh LB or TB was inoculated with the 
overnight bacteria and grown for 4 hours at 37°C until OD600= 0.6-1.0. Expression of 
APT1 was induced with final concentration of 1 mM IPTG for 2 hours at 37°C or 
overnight at 18oC. Cells were pelleted at 8000 RPM for 15 minutes at 4°C. Pellet was 
resuspended in 50 mM HEPES pH 8.0, 300 mM NaCl, 1% Triton X-100, 20 mM 
Imidazole (Sigma), 1 mM Phenylmethylsulfonyl fluoride (PMSF), 1 mM dithiothreitol or 
25 mM HEPES pH 7.5, 500mM NaCl, 10% glycerol, 1mM PMSF, 10mM 2-
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Mercaptoethanol, complete EDTA free protease inhibitor cocktail (Pierce). Lysate was 
sonicated at 50% duty cycle for 30 second pulses two times on ice or 50% duty cycle for 
30 pulses on and 30 pulses off for 30 minutes at 4oC. Lysate was centrifuged at 12,000 
RPM for 15 minutes at 4°C. Supernatant was incubated with Ni Sepharose 6 Fast Flow 
beads (GE Healthcare) at 4°C rocking for 3 hours or overnight. Beads were washed 
three times with wash buffer (50mM HEPES pH 8.0, 300mM NaCl, 40mM Imidazole) or 
500mL of wash buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 40 mM 
Imidazole, 10mM 2-Mercaptoethanol). Protein was eluted using 50 mM HEPES pH 8.0, 
300 mM NaCl, 250 mM Imidazole by rocking for 45 minutes at 4°C or 50mL of 25 mM 
HEPES pH 7.5, 500mM NaCl, 300mM Imidazole, 10mM 2-Mercaptoethanol at 4°C. For 
SEC experiments, 50 mL of eluted APT1 was dialyzed against 25 mM HEPES pH7.5, 
150mM NaCl, 10mM 2-Mercaptoethanol overnight at 4°C. Dialyzed APT1 was 
concentrated using an Amicon Ultra-15 centrifugal filter unit to 500 µL and injected onto 
NGC Liquid Chromatography System (Bio-Rad) equipped with a Superdex 200 Increase 
10/300GL (GE) size-exclusion chromatography (SEC) equilibrated in 25 mM HEPES 
pH7.5, 150mM NaCl, 10mM 2-Mercaptoethanol. Fractions containing homogeneous 
APT1 were utilized for analytical SEC at various protein concentrations.   
Fluorogenic palmitoyl thioesterase assays 
APT1 was assayed for depalmitoylating activity as described previously (Kathayat et al. 
2017). 
Fluorogenic palmitoyl thioesterase assay from immunopurified APT1-CFP-FLAG 
WM239A cells ectopically expressing APT1-CFP-FLAG mutants were treated with 
control buffer or 150 ng/ml of purified Wnt5a and lysed in lysis buffer containing 1% 
63 
 
Triton-X 100, 50 mM Tris pH 7.5, 150 mM NaCl supplemented with protease and 
phosphatase inhibitors (1µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml pepstatin A, 1mM 
PPi, 2nM NaVO4, 150mM NaF). Insoluble cell debris was removed by centrifugation 
(13,000 RPM for 10 min at 4°C. Lysate was incubated with FLAG M2 magnetic beads 
(Sigma-Aldrich, St. Louis, MO) for 1.5 hours. Beads were washed with lysis buffer and 
fluorogenic palmitoyl thioesterase assay was performed as described previously 
(Kathayat et al. 2017). 
Crosslinking Experiments 
APT1 mutants were purified using technique mentioned above. After quantification, 4.5 
µM of APT1 was incubated with the following buffer for a final concentration of 35 mM 
HEPES pH 8, 210 mM NaCl. All crosslinking experiments were crosslinked with a final 
concentration of 1mg/ml disuccinimidyl glutarate, over time. Crosslinking was quenched 
by incubating samples with 5X SDS loading buffer and boiled.  
Differential scanning fluorimetry 
Differential scanning fluorimetry data were collected on a QuantStudio3TM Real-Time 
PCR Detection System (Applied Biosystems) at a APT1 protein concentration of 1.42 µM 
in either 50 mM HEPES pH 8.0 using SYPRO orange as described previously 
{Niesen:2007eh}. The melting temperature was calculated by fitting the normalized data 
curve to  the Boltzmann sigmoid equation in Prism 6 (GraphPad) as described 
previously{Niesen:2007eh}. 
Size-exclusion chromatography 
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Homogenous APT1WT or APT1S209D at 0.1 mg/mL, 0.25 mg/mL, or 0.375 mg/mL were 
injected onto NGC Liquid Chromatography System (Bio-Rad) equipped with a Superdex 
200 Increase 10/300GL (GE) size-exclusion chromatography (SEC) equilibrated in 25 
mM HEPES pH 7.5, 150 mM NaCl, 10 mM 2-Mercaptoethanol. Fractions corresponding 
to molecular weight standards between 44kD (Ovalbumin) and 29kD (Carbonic 
anhydrase) were evaluated by Coomassie Brilliant Blue (CBB).  
Enzyme kinetics 
Purified APT1 protein (purification mentioned above) was incubated with increasing 
concentrations of DPP-3 substrate and fluorescence was measured over time to 
measure depalmitoylation (Kathayat et al. 2017). Initial velocities were calculated by 
fitting the linear regression of the fluorescence vs. time for APT1WT or APT1S209D at each 
DPP-3 substrate concentration.  
Immunohistochemistry 
Melanoma tumor arrays (US Biomax, Inc, ME1004b and ME1004e) were immuno-
stained with primary antibody 1:50 anti-pS209APT1 and 1:200 anti-APT1. Staining 
procedure was performed as described in Walter et al., 2017. Images were obtained 
using 20X objective using a Leica DMI6000 B inverted microscope. 
Statistics 
* denotes a P-value between 0.0150-0.0205, ** denotes a P-value of 0.0017 and **** 
denotes a P-value of less than 0.0001 in an unpaired, two-tailed Students t-test, 
assuming normal distribution and equal variance. Each experiment was performed at 
least three times. 
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CHAPTER 4: IDENTIFYING APT1’S KINASE 
 
OVERVIEW 
 After discovering Wnt5a signaling results in the phosphorylation of APT1, 
increasing its depalmitoylating activity to promote melanoma invasion, the obvious 
question remained unanswered: What is the identity of the candidate kinase responsible 
for phosphorylating APT1 in response to activation of Wnt5a signaling? My advisor, Eric 
S. Witze, obtained data from a previous screen used in a publication (Witze et al., 2013) 
where he performed proteomics profiling to determine changes in localization of proteins 
in response to Wnt5a treatment. In that screen, he identified lymphocyte-oriented kinase, 
hereon referred to as LOK and also known as STK10, became associated with the 
cytoskeleton in response to Wnt5a treatment. This led us to investigate LOK’s candidacy 
in being the Wnt5a responsive kinase for APT1’s serine’s 209/210. 
 
INTRODUCTION 
LOK belongs to the Ste20 family of serine/threonine kinases. LOK, also referred 
to as lymphocyte-oriented kinase or STK10 (serine/threonine kinase 10), had been 
previously reported as highly expressed in lymphocytes in mice and similar expression 
patterns are observed in human tissues. Additionally, LOK is expressed highest in 
rapidly proliferating tissues but is also detected in other tissues profiled (Walter et al., 
2003). Interestingly, LOK was detected in many different tumor cells lines and has the 
ability to auto-phosphorylate itself (Walter et al., 2003). LOK has been determined to be 
a major ERM kinase that phosphorylates ERM proteins to regulate cortical 
reorganization through the following observations: identification of LOK colocalizing with 
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cpERM (C terminus phosphorylated ERM), confirming LOK phosphorylates ERM 
proteins and determining LOK knockout mice have decreased ERM phosphorylation 
(Belkina et al., 2009). ERM (ezrin-radixin-moesin) proteins regulate linkage of the actin 
cytoskeleton to the plasma membrane and rapid dephosphorylation of these proteins 
facilitates lymphocyte polarization (Belkina et al., 2009, Brown et al., 2003). Additionally, 
ERM N-terminus binds to the plasma membrane by both direct interactions with 
phospholipids and by binding cytoplasmic tails of transmembrane proteins such as 
CD44.   
After parsing out the data of kinases in WM239A cells that become associated 
with the cytoskeleton in response to Wnt5a treatment, STK10 kinase (or LOK) was 
determined to have a shifted peak in the Wnt5a treatment sample, showing an increase 
in abundance in the organelle fraction containing the cytoskeleton (data from screen 
used in Witze et al., 2013). LOK was the only kinase that was detected in this screen to 
have any sort of shift in organelle association in response to Wnt5a. This preliminary 
data suggests LOK becomes associated with the cytoskeleton in response to Wnt5a 
signaling. Since LOK fits the profile of being a serine/threonine kinase, in combination 
with the Wnt5a-mediated cytoskeletal association, we hypothesized this kinase might be 
APT1’s Wnt5a regulated kinase responsible for phosphorylating APT1 on serine’s 
209/210 in response to Wnt5a signaling, regulating downstream events such as 
depalmitoylation of cell adhesion molecules and ultimately promoting melanoma 
invasion. 
 
RESULTS 
Inhibition or knockdown of LOK reduces pAPT1 levels and Wnt5a treatment 
increases LOK-MCAM interactions 
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 After reviewing Witze et al., 2013 database of kinases that shifted their 
abundance in various organelle fractions, STK10, hereon referred to as LOK, was found 
to have increased abundance in the cytoskeletal fractions in response to Wnt5a 
stimulation (Figure 4.1A, adapted from data obtained in Witze et al, 2013). These results 
suggest Wnt5a signaling promotes LOK association to the cytoskeleton. Since Wnt5a 
treatment is inducing an increased association with the cytoskeleton, there was the 
possibility that LOK could be changing its intracellular localization in response to Wnt5a 
signaling. We questioned if we could observe the changes in LOK’s localization in 
response to Wnt5a signaling. By the same token, we were interested if we could detect 
any similarities to MCAM’s asymmetrical localization response to Wnt5a signaling by 
determining if LOK also becomes asymmetrically localized in Wnt5a treated cells. To 
answer this question, we performed immunostaining of fixed WM239A cells to compare 
the localization of MCAM and LOK post-Wnt5a treatment, followed by 
immunofluorescence imaging. Treatment of WM239A cells with purified Wnt5a results in 
asymmetric localization of not only MCAM, as expected, but also LOK (Figure 4.1B). If 
Wnt5a signaling results in asymmetric localization of LOK, we wanted to understand how 
LOK’s localization was being modified following Wnt5a treatment. As we described in 
detail in the earlier chapters, protein palmitoylation is known to regulate protein 
localization. Our lab has shown Wnt5a signaling regulates protein palmitoylation status 
of various proteins. The evidence showing LOK becomes asymmetrically localized in 
response to Wnt5a led us to ask the question, is LOK palmitoylated? The abundance of 
palmitoylated LOK in each condition was then measured using the acyl-biotin exchange 
assay (ABE) in parental WM239A cells and APT1WT expressing WM239A cells. As a 
negative control, samples are processed without hydroxylamine (-HAM) leaving the 
palmitoylated cysteines intact and preventing biotin labeling. We found LOK to be 
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palmitoylated in both parental WM239A cells and APT1WT expressing cells (Figure 
4.1C). These results suggest LOK can be palmitoylated and palmitoylation could be the 
mechanism driving asymmetric localization of LOK in response to activated Wnt5a 
signaling. Our next goal was to determine if phosphorylation of APT1 is reduced with 
LOK inhibition.  
BI-D1870 is an ATP analog, which acts as an ATP competitor, and is known to 
inhibit LOK’s kinase activity (Edgar et al., 2014). We treated WM239A APT1WT cells with 
either control buffer or purified Wnt5a and DSMO or 10 µM of BI-D1870, immunopurified 
APT1 with anti-FLAG magnetic beads, processed the samples by SDS-PAGE, and 
blotted for pS209APT1 to determine the phospho-APT1 levels. Inhibition of LOK with BI-
D1870 treatment results in a reduction in phospho-APT1 levels (Figure 4.1D). We 
generated a short-hairpin to LOK in order to study how knockdown of LOK affects 
phosphorylation of APT1. Knockdown of LOK reduces phospho-APT1 levels compared 
to control cells (Figure 4.1E). These results suggest LOK is necessary to phosphorylate 
APT1 and LOK phosphorylates APT1 in response to Wnt5a signaling.  
After determining LOK is asymmetrically localized in response to Wnt5a, and 
located in close proximity to MCAM in the cell via our imaging experiments, we asked do 
LOK and MCAM interact? Parental and APT1WT expressing WM239A cells were treated 
with control buffer or purified Wnt5a, endogenous MCAM was immunopurified, and LOK-
MCAM interaction was determined by SDS-PAGE followed by immunoblotting for LOK. 
In the basal control buffer-treated state, LOK is unable to be pulled down with MCAM. 
However, in Wnt5a treated cells LOK is co-immunoprecipitated with MCAM (Figure 
4.1F). Not only does Wnt5a signaling induce increased interaction of LOK and MCAM, 
but this interaction is augmented with ectopic expression of APT1 (Figure 4.1F). This 
observation leads us to conclude APT1 is increasing LOK-MCAM interactions, likely 
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through a complex formation. Since APT1 expression clearly augments LOK-MCAM 
interactions, we asked if a depalmitoylation mutant of MCAM, MCAMC590G would be able 
to interact with LOK.  Our hypothesis was that APT1 would not be necessary for 
depalmitoylation of MCAM, and thus regardless of Wnt5a treatment, the APT1-LOK 
complex would then not interact with the palmitoylation mutant of MCAM (MCAMC590G, 
hereon referred to as MCAMCG). Cells expressing APT1WT as a control, or MCAMWT or 
MCAMCG were treated with control buffer or purified Wnt5a. MCAM was immunopurified 
and we detected LOK levels by immunoblotting. Palmitoylation mutant MCAMCG is 
unable to pull down LOK, while in APT1WT and MCAMWT expressing cells MCAM 
interacts with LOK in response to Wnt5a stimulation (Figure 4.1G). This might suggest 
that LOK phosphorylating APT1 is the event that promotes LOK-MCAM interactions. 
Then, when MCAM is unable to be depalmitoylated, it doesn’t end up interacting with the 
APT1/LOK complex. With these results combined, we determined LOK can be 
palmitoylated, is asymmetrically localized in response to Wnt5a, is able to interact with 
MCAM, and inhibition or knockdown of LOK reduces phospho-APT1 levels. We wanted 
to better understand LOKs role in the ability of the Wnt5a signaling pathway to promote 
metastatic behavior.  
 
Inhibition or knockdown of LOK inhibits Wnt5a induced melanoma invasion 
Since inhibition or knockdown of LOK reduces phospho-APT1 levels, we wanted 
to better understand if inhibition and/or knockdown of LOK could block Wnt5a induced 
melanoma invasion. Previously, we have shown Wnt5a induced melanoma invasion 
requires APT1 activity, and APT1 activity can be increased through phosphorylation of 
APT1. If LOK is the kinase that phosphorylates APT1, and thereby increases its 
depalmitoylating activity, then inhibition or knockdown of LOK should reduce Wnt5a 
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stimulated melanoma invasion. We treated WM239A melanoma spheroids embedded in 
collagen with purified Wnt5a and either DSMO or 10 µM BI-D1870 every other day and 
measured invasion on day 7. Treatment of WM239A spheroids with BI-D1870 
significantly reduced melanoma invasion compared to DSMO negative control (Figure 
4.2A). Similarly, in APT1WT cells, treatment with BI-D1870 reduces melanoma invasion 
(Figure 4.2B). When we combine that data to compare the values observed with 
WM239A parental cells and those expressing APT1WT, we see that even APT1WT cells’ 
high invasiveness is reduced with BI-1870 treatment (Figure 4.2C). This tells us that 
inhibition of LOK can significantly reduce Wnt5a induced melanoma invasion.  
Next, we treated APT1WT control, and two clones of shLOK, shLOK2.3, and 
shLOK2.4 melanoma spheroids cells embedded with collagen with purified Wnt5a and 
measured melanoma invasion on day 7. APT1WT control cells display a high level of 
invasiveness, as expected since the spheroids are treated with Wnt5a which promotes 
invasion (Figure 4.2D, 4.2F). Knockdown of LOK, shown with two shRNA clones, 
dramatically reduces Wnt5a mediated invasion in melanoma cells in both parental 
WM239A and APT1WT expressing cells (Figure 4.2D, 4.2E, 4.2F). Taken together, these 
results suggest APT1 phosphorylation, mediated by LOK, is driving melanoma invasion 
and that LOK inhibition or knockdown can significantly reduce Wnt5a induced melanoma 
invasion.  
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FIGURES 
 
Figure 4.1. Inhibition or knockdown of LOK/STK10 reduces pAPT1 levels and Wnt5a 
treatment increases LOK-MCAM interactions. (A) Proteomics profiling of Wnt5a treated 
WM239A melanoma cell lysates, with LOK kinase, also known as STK10, results shown. 
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(Data obtained through screen from Witze, E., et al., 2013). Lysates were subjugated to 
density gradient centrifugation followed by protein digestion and mass spectrometry. 
Fraction 2 corresponds to the cytoskeleton fraction. (B) Immunostaining of Wnt5a 
treated WM239A cells and cellular localization of LOK and MCAM observed by 
immunofluorescence microscopy. DAPI staining indicates nuclei. Merge images 
combines all filtered images shown. (C) Acyl-biotin exchange assay of WM239A control 
and APT1WT cells showing palmitoylation levels of LOK (Palm LOK) compared to total 
LOK by western blot analysis using anti-LOK antibodies. (D) WM239A ectopically 
expressing APT1WT were treated with control buffer or 150 ng/ml of purified Wnt5a and 
either DSMO or 10 µM of BI-D1870. APT1WT was immunopurified and phosphorylation 
levels of APT1 was analyzed by western blot analysis. (E) Western blot of WM239A 
APT1WT control and APT1WT shLOK cells treated with control buffer or 150 ng/ml purified 
Wnt5a. APT1 was then immunopurified to determine phospho-APT1 levels using 
pS209APT1 antibodies. β-actin was immunoblotted for as a loading control. (F) 
WM239A control or APT1WT cells were treated with control buffer or 150 ng/ml purified 
Wnt5a, MCAM was immunopurified, samples analyzed by SDS-PAGE, and 
immunoblotted for LOK. (G) WM239A cells ectopically expressing APT1WT, MCAMWT, or 
MCAMC590G (MCAMCG) were treated with control buffer or 150 ng/ml Wnt5a, MCAM was 
immunopurified, samples analyzed by SDS-PAGE, and immunoblotted for LOK using 
anti-LOK antibodies. 
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Figure 4.2. Inhibition or knockdown of LOK/STK10 inhibits Wnt5a induced melanoma 
invasion. (A) WM239A melanoma cells were grown on agarose to form spheroids that 
were embedded in collagen, purified Wnt5a and DSMO or 10 µM BI-D1870 were added 
to the wells every other day, images were taken on day 7, and the distance invaded was 
measured. Quantification of WM239A spheroid invasion assay. n=4 spheroids counted 
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per condition, **p=0.0044 by unpaired t-test analysis. (B) WM239A APT1WT cells were 
grown on agarose to form spheroids that were embedded in collagen, purified Wnt5a 
and DSMO or 10 µM BI-D1870 were added to the wells every other day, images were 
taken on day 7, and the distance invaded was measured. Quantification of WM239A 
spheroid invasion assay. n=4 spheroids counted per condition, **p=0.0036 by unpaired 
t-test analysis. (C) Combined data from (A) and (B). (D) WM239A APT1WT control, two 
clones of shLOK, shLOK2.3 and shLOK2.4, cells were grown on agarose to form 
spheroids that were embedded in collagen, purified Wnt5a and DSMO or 10 µM BI-
D1870 were added to the wells every other day, images were taken on day 7, and the 
distance invaded was measured. Representative images of each sample are shown. (E) 
Quantification of WM239A spheroid invasion assay of control and shLOK cells. n=4 
spheroids counted per condition. *p=0.0113 by unpaired t-test analysis.  (F) 
Quantification of WM239A APT1WT spheroid invasion assay of control and shLOK cells. 
n=4 spheroids counted per condition. *p=0.0274 by unpaired t-test analysis.   
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DISCUSSION 
Here, we uncover evidence to suggest LOK may be the Wnt5a-mediated kinase 
that phosphorylates APT1 in response to activation of the Wnt5a pathway in melanoma. 
We have shown LOK to be palmitoylated, something that had not yet been reported. 
Having this kinase be spatially regulated by palmitoylation opens up the possibility that 
LOK’s regulation itself can go awry in cancer cells who have palmitoylation in palmitoyl 
transferases. Identification of LOK’s palmitoylation sites might help us better understand 
how LOK’s palmitoylated state affects its interactions with its targets. Furthermore, 
identification of LOKs palmitoyltransferase will help us piece together this puzzle. If 
LOKs palmitoyl transferase is also mutated frequently in cancer, there are other ways 
this signaling pathway can be augmented to promote metastasis, as well as other angles 
to pursue in terms of therapeutic options. It’s important to also investigate how LOKs 
palmitoylation status affects its ability to interact with other LOK targets. For example, if 
palmitoylation blocks, or conversely increases, LOKs ability to phosphorylate ERM 
proteins and influences how cells migrate, then increased palmitoylation cycling 
regulated by Wnt5a signaling could be affecting more than APT1 activity but also 
downstream players that promote migration. Understanding how palmitoylation of LOK 
affects its interaction with its targets and the ability to phosphorylate them is an important 
next step for us to investigate to better understand LOKs role in normal, untransformed 
cells, and the role it plays in promoting cancer metastasis. 
Our findings of LOK’s Wnt5a-induced asymmetry can be interpreted in different 
ways. One possibility is that activation of Wnt5a signaling could result in an adaptor or 
scaffolding proteins increased interaction with LOK, such as Dvl, which we know plays a 
role in Wnt signaling. The scaffolding protein could bring the kinase in close proximity to 
APT1 so that it can be phosphorylated, and this event is responsible for the Wnt5a-
76 
 
induced asymmetry of LOK that we observe. Another possibility is Wnt5a signaling 
results in LOK becoming depalmitoylated, and the depalmitoylation of LOK is what is 
responsible for LOKs induced asymmetry, and there it interacts with APT1 alone. One 
way to start to determine if Dvl is binding LOK to bring it in close proximity to APT1 is to 
answer the question, do Dvl and LOK interact? One could perform co-
immunoprecipitation assays and reciprocal co-immunoprecipitation assays to determine 
if they interact in a complex. After that, one could clone the various domains of Dvl to 
determine which domain specifically is responsible for this interaction by co-
immunoprecipitation experiments. To determine if asymmetric LOK is primarily in its 
palmitoylated or depalmitoylated state, one could perform an acyl-biotin exchange assay 
on fixed cells on a coverslip and then image via fluorescence microscopy. If 
depalmitoylated LOK is mainly asymmetrical, this might provide us with evidence that 
LOK is depalmitoylated, and once its depalmitoylated it is able to move freely about the 
cell, either on its own or as part of a complex, to act on downstream targets such as 
APT1.  Another added layer of mechanistic clarity would be provided if live imaging 
experiments were performed using tagged LOK and MCAM to determine the temporal 
events and can be used to define which of these players becomes asymmetrical in 
response to Wnt5a first, or if they occur at the same time. 
If somehow, activation of Wnt5a signaling is activating LOK itself to 
phosphorylate APT1, LOK activation could potentially have a feedback loop associated 
with it. It would be interesting to investigate if any modifications arise in LOK post Wnt5a 
treatment, especially since we know LOK can phosphorylate itself. For example, Wnt5a 
signaling could result in LOK itself being phosphorylated by either itself or another 
kinase, and this could be an explanation for increased phosphorylation of APT1 in 
response to Wnt5a signaling. That observation, in combination with LOK being 
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palmitoylated/depalmitoylated, adds an extra layer to LOK regulation. Palmitoylation of 
LOK could be part of the feedback loop proposed. A potential mechanism can include 
any of the following two possibilities. Wnt5a signaling increasing LOK’s proximity to 
APT1 or Wnt5a signaling results in a regulatory modification of LOK, such as 
phosphorylation or autophosphorylation or palmitoylation/depalmitoylation, to increase 
its affinity for APT1. Of course, there is the possibility that both of these are involved in 
some capacity in the mechanism of how LOK phosphorylates APT1 in response to 
Wnt5a signaling. Further studies would need to be performed to tease out these details. 
 
METHODS 
Purification of recombinant Wnt5a and treatments with Wnt5a 
Wnt5a was purified from mouse L-cells overexpressing human Wnt5a as described 
previously (Willert et al., 2003). Control cells were treated with control buffer with 
identical detergent conditions as the Wnt5a purification buffer.  
Cell lines and culture conditions 
Metastatic melanoma cell line WM239A (BRAF V600D) (Wistar Institute) were cultured 
in RPMI 1640 medium (Gibco-BRL, Grand Island, NY) supplemented with 10% fetal 
bovine serum (FBS) (GE Life Sciences). Cell lines were authenticated routinely by short 
tandem repeat profiling by the Wistar Institute prior to use. 
Immunoprecipitation 
WM239A cells ectopically expressing APT1-CFP-FLAG mutants were treated with 
control buffer or 150 ng/ml Wnt5a for specified time period and then lysed in lysis buffer 
containing 1% Triton-X 100, 50 mM Tris pH 7.5, 150 mM NaCl supplemented with 
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protease and phosphatase inhibitors (1µg/ml leupeptin, 1µg/ml aprotinin, 2µg/ml 
pepstatin A, 1mM PPi, 2nM NaVO4, 150mM NaF). Insoluble cell debris was removed by 
centrifugation (13,000 RPM for 10 min at 4°C. Lysate was incubated with FLAG M2 
magnetic beads (Sigma-Aldrich, St. Louis, MO) for 1.5 hours. Beads were washed with 
lysis buffer and protein was eluted using FLAG peptide for 1 hour at room temperature. 
Samples were separated by SDS-PAGE and transferred to either nitrocellulose 
membrane (Life Technologies, Thermo Fisher Scientific, Waltham, MA) for phospho-
APT1 antibody (YenZym Antibodies, San Francisco, CA) or PVDF membrane (Millipore, 
Burlington, MA) for all other antibodies used. 
Western blot analysis and antibodies 
Cells were harvested and lysed in 1% Triton X-100, 50mM Tris pH 7.5, 150mM NaCl 
supplemented with protease and phosphatase inhibitors (1µg/ml leupeptin, 1µg/ml 
aprotinin, 2µg/ml pepstatin A, 1mM PPi, 2nM NaVO4, 150mM NaF). Insoluble cell debris 
was removed by centrifugation (13,000 RPM for 10 min at 4°C. The protein 
concentration was determined by DC Protein method (BioRad, Hercules, CA). Equal 
amounts of total protein were separated by SDS-PAGE and transferred to either 
nitrocellulose membrane (Life Technologies, Thermo Fisher Scientific, Waltham, MA) for 
phosphor-APT1 antibody or PVDF membrane (Millipore, Burlington, MA) for all other 
antibodies used. The nitrocellulose membranes were blocked with 5% bovine serum 
albumin (BSA) in TBST (TBS, 0.1% Tween). The PVDF membranes were blocked with 
5% dry milk in TBST. All membranes were immunoblotted with different antibodies 
diluted in 5% BSA in TBST.  
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The rabbit anti-human APT1 antibody (Abcam, Cambridge, MA) was used at 1:1000. 
The rabbit anti-human beta-actin (Cell Signaling Technologies, Danvers, MA) was used 
at 1:5000. The mouse anti-human MCAM antibody (Santa Cruz Biotechnology, Dallas, 
TX) was used at 1:1000. The rabbit anti-human LOK antibody was use 1:1000 (Bethyl 
Laboratories, Montgomery, TX). The secondary antibodies were HRP-conjugated 
1:10000 diluted in 5% BSA in TBST. Membranes were washed three times with TBST 
between the different steps.  
Immunofluorescence 
Parental WM239A cells were plated on glass coverslips and treated with 150 ng/ml 
purified Wnt5a, fixed with formalin solution (10% neutral buffered) for 10 minutes, and 
cell membranes were permeabilized with 0.1% Triton X-100 in PBS for 10 minutes, and 
blocked with 5% BSA in TBST solution for 30 minutes. Primary antibodies of MCAM 
(Santa Cruz Biotechnology, Dallas, TX) and LOK (Bethyl Laboratories, Montgomery, TX) 
were added 1:500 overnight at 4°C. Primary antibody was washed off with three washes 
of TBST. Secondary antibodies were added at 1:1000 for 1 hour at room temperature, 
washed in TBST, and mounted with DAPI mount (SouthernBiotech, Birmingham, AL). 
Cells were imaged using Leica DMI6000 B inverted microscope.  
Acyl-biotin exchange assay 
The ABE assay was performed as described (Wan et al., 2007). 
Spheroid assay 
96-well plates were coated with 50 µl per well of sterile 1.5% noble agar and solidified at 
room temperature for 10 min. 200 µl of 2.5 × 104 cells/ml cell suspension was added to 
each well. Spheroids formed at 37°C and at 4% CO2 for 48 h. Collagen matrices were 
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prepared on ice using Pur Col purified bovine collagen (Advanced Biomatrix, Carlsbad, 
CA), Hyclone RPMI 1640 (5X) with sodium biocarbonate diluted to 1X in total volume 
and 10% FBS. Sterile NaOH was added to correct the collagen pH. 75 µl of collagen 
matrix was added to new wells and allowed to solidify at 37°C for 1 h. Spheroids were 
resuspended in 125 µl of collagen matrix and transferred to wells containing 75 µl of 
collagen. After collagen solidified at 37°C, 100 µl of fresh medium was added on top of 
the collagen. Medium was changed every other day. Images were taken every 24 h for 1 
– 10 days. For the invasion assays including BID-1870: 10µM of BID-1870 (Sigma-
Aldrich, St. Louis, MO) was added to fresh media on the spheroids and changed every 
other day. 
Statistics 
* denotes a P-value between 0.0113-0.0274, ** denotes a P-value of 0.0036-0.0044 in 
unpaired two-tailed Students t-test, assuming normal distribution and equal variance. 
Each experiment was performed at least 3 times. 
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CHAPTER 5: FUTURE DIRECTIONS 
 
OVERVIEW 
 As we summarize our findings and conclude our discussion, we end with an 
examination on future directions of this thesis project. We provide proposals for future 
experiments that will validate our findings, make suggestions of various avenues to 
pursue that could provide valuable insight, and outline how breakthroughs on defining 
this pathway further can open up possibilities to create better therapies for cancer 
patients.  
 
CONFIRMING LOK AS APT1’S KINASE 
 More experiments confirming LOK as APT1’s candidate kinase must be 
performed in order to validate our findings. One could strengthen this argument by 
cloning a recombinant catalytically inactive mutant of LOK, expressing this in WM239A 
cells, treating the cells with purified Wnt5a, and determining the levels of phosphorylated 
APT1. We expect catalytically inactive LOK would be unable to phosphorylate APT1 and 
thus, we would not be able to detect phospho-APT1. Conversely, if one were to clone 
LOK and perform an in vitro kinase assay with purified APT1, we would expect LOK to 
be sufficient to phosphorylate APT1.  
Our findings of LOK’s Wnt5a induced asymmetry and its temporal response 
remain to be validated. It would be interesting and valuable to determine the temporal 
events that result in Wnt5a induced asymmetry of LOK and if this occurs before, during, 
or after MCAM’s Wnt5a induced asymmetry. By creating different fluorescently tagged 
LOK and MCAM, we could perform live cell imaging experiments on Wnt5a treated 
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WM239A cells and observe the timing of the asymmetry. Particularly, it would be 
interesting to determine if we performed that same experiment with catalytic inactive 
LOK or with a palmitoylation mutant of LOK, after the LOK sites have been mapped, if 
this would change the Wnt5a induced asymmetry. Based on my initial observations, I 
would hypothesize the palmitoylation mutant LOK would no longer be able to be 
asymmetrically distributed in response to Wnt5a signaling. As far as the catalytic inactive 
mutant, we would need to understand how LOKs catalytic activity affects it assembling in 
a LOK-MCAM-APT1 complex, if it does. Hence, further studies would need to be done to 
clarify this sort of complex and what regulates it.  
How LOK becomes primed for APT1 phosphorylation in response to Wnt5a 
signaling remains unknown. Understanding how activation of Wnt5a signaling leads to 
increased phosphorylation of APT1 by LOK is important to understand and parsing out 
the other pathway players involved in this signaling axis would help provide clarity to this 
issue. One possibility is cytosolic adaptor or scaffold proteins, such as Dishevelled, 
bringing LOK in close proximity to APT1. Activation of Wnt5a-Ror signaling has been 
shown to phosphorylate the scaffolding protein Dishevelled (Dvl), while the absence of 
Ror signaling leads to a phenotype that mirrors Wnt5a null mutant mice (Ho et al., 2012), 
providing evidence that Dvl is a Wnt5a-Ror signaling target. I have obtained preliminary 
evidence that Dvl binds APT1 shown by a co-immunoprecipitation of APT1 and Dvl. For 
this reason, generating Dvl domain mutants and determining if Dvl can bind to LOK, or 
any of the depalmitoylation targets of APT1, such as MCAM and CD44, would help 
tease out the role Dvl plays in the Wnt5a/APT1 signaling axis.  
Other unanswered questions remain within LOK’s palmitoylation and regulation 
of palmitoylation. For example, the identification of the palmitoyl transferase responsible 
for palmitoylating LOK remains unknown. Additionally, identifying the palmitoylation 
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site(s) on LOK would be another important piece of information that would help us 
understand how LOK’s activity and function could be regulated. One could map the likely 
palmitoylation sites by looking at the various LOK domains, identify the cysteines, map 
those via a palmitoylation software, and then create palmitoylation mutants of each to 
study which of those cysteines are the likely palmitoylation targets using acyl-biotin 
exchange assays. In addition, it would be interesting to determine if LOK is 
depalmitoylated by APT1. If we review Figure 4.1C, where we show LOK’s 
palmitoylation levels, they appear to be lower in the cells ectopically expressing APT1WT 
which would suggest APT1 can depalmitoylate LOK. It would be interesting to 
investigate how expressing the APT1 phospho-mutants, APT1SA and APT1SD, and then 
measure the effects LOK palmitoylation levels. If the high activity of APT1SD, or phospho-
APT1, are overserved with LOK as a substrate, and there are decreased LOK 
palmitoylation levels when you express APT1SD, then this could suggest APT1 regulating 
LOK’s localization in a feedback mechanism. LOK could phosphorylate APT1, APT1 can 
then become ‘activated’, depalmitoylate LOK, and LOK can then become more dynamic 
in the cell, allowing more freedom for movement throughout the cell and asymmetric 
localize. One possibility is this feedback loop allows LOK to better access its targets, 
another is that it could increase APT1’s phosphorylation in specific areas of the cell so 
that APT1 can increase its depalmitoylated of targets. This possibility, alongside or in 
combination with the scaffolding complex, might help explain why we see the 
asymmetric localization of LOK in response to Wnt5a. If LOK is able to re-localize to a 
specific region of the cell, then there it could phosphorylate other downstream targets, 
such as ERM proteins, which could be resulting in changes in the cytoskeleton and thus, 
increased migration and motility.  
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IDENTIFICATION OF OTHER PROTEINS THAT MIGHT PLAY A ROLE IN THE 
WNT5A SIGNALING PATHWAY 
 More than 2000 human proteins have either been shown or predicted to be 
palmitoylated (Blanc et al., 2015). This represents 12% of the proteome and 
identification of the proteins whose depalmitoylation is Wnt5a responsive would provide 
further clarity on downstream players and the role they play in promoting metastasis. We 
know many proteins are palmitoylated and palmitoylation can affect how they signal, 
traffic, and how they interact with their pathway players. However, detailing the events 
that cause their palmitoylation or depalmitoylation are yet to be provided for many of 
palmitoylated proteins. To better understand the role Wnt5a signaling plays on the global 
palmitoylation landscape, I treated WM239A cells with control buffer or purified Wnt5a, 
performed an acyl-biotin exchange assay, processed samples by SDS-PAGE, and 
determined the global palmitoylation landscape proteins by silver stain analysis. Many 
bands appear in the control buffer lane, indicating a large number of palmitoylated 
proteins exist in the untreated state, while a large selection of those bands disappear in 
the Wnt5a treated sample, suggesting they are no longer in their palmitoylated state 
when Wnt5a signaling is activated. When we treat the cells with an APT inhibitor, 
Palmostatin B, prior to Wnt5a treatment, and then perform the same analysis, many 
bands return that disappeared in the Wnt5a treated sample. This suggests APT1 activity 
is required for the Wnt5a mediated depalmitoylation of those proteins. This preliminary 
data I obtained suggests Wnt5a signaling promotes a large subset of proteins to be 
depalmitoylated, and this is specifically mediated by APT1 activity (data not shown). It 
would be interesting to identify those proteins that are depalmitoylated by APT1 in 
response to Wnt5a signaling. With this information, we can begin testing how their 
palmitoylation state affects their function and overall cell behavior, and how those 
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proteins play a role in metastasis. One could perform the same experiment, but instead 
of a silver stain analysis one could perform a Coomassie stain and analyze the 
differences via mass spectrometry analysis to identify the proteins. Once the candidates 
have been identified, test their how palmitoylation state affects metastatic behavior. This 
may help round out the picture of how palmitoylated/depalmitoylated proteins are 
promoting metastasis.   
 
UNDERSTANDING THE ROLE OF APT1 PHOSPHORYLATION IN VIVO 
 Understanding APT1’s activity in vivo would provide invaluable information on 
how phosphorylated APT1 functions in tissues. We could do this by introducing APT1 
wild-type and the APT1 phospho-mutants into human melanoma cells or into 
transformed primary human melanocytes and study melanoma invasion via an 
organotypic model. This type of model allows us to recapitulate the human skin by using 
all human components including keratinocytes, primary melanocytes, basement 
membranes, and investigate three-dimensional melanoma invasion on a mouse (Ridky 
et al., 2010). We can introduce genetic events that are commonly found in human 
melanoma, such as BRAFV600E and p53 inactivation, and the wild-type or phospho-
mutants of APT1, allow the skin to grow, graft it onto a mouse, and study melanoma 
invasion over time by examining invasion through immunostaining after time. Validating 
phospho-APT1 or the disease-relevant mutation, APT1S209D and APT1S210L, respectively, 
increase metastatic behavior in vivo would further strengthen the argument that Wnt5a 
induced phosphorylation of APT1, or patients who present with this mutation in their 
melanoma, are likely to have metastatic disease. An alternative technique to do this to 
remove the possibilities of issues with overexpression vectors is to mutate the 
endogenous APT1 using CRISPR technology.  
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INVESTIGATING THE WNT5A/APT1 SIGNALING AXIS IN OTHER CANCERS 
Other studies have investigated Wnt5a’s role in cancer cell migration, 
proliferation, and survival across a wide variety of tumor types. Wnt5a enhances 
activation of Rac1/2 by inducing receptor tyrosine kinase-like orphan receptor 1 (Ror1) to 
interact with DOCK2, leading to Wnt5a enhanced cell proliferation (Hasan et al., 2018). 
Previous studies have down a role for Wnt5a in osteosarcoma. Wnt5a stimulates 
migration and invasion of osteosarcoma cells (Wang, X. et al 2018). Similarly, Wnt5a-
induced cell migration in osteosarcoma cells is through activation of PI3K/Akt/RhoA 
signaling (Dai et al., 2018).  
 It is worth investigating the Wnt5a/APT1 signaling axis in other cancers to 
confirm the mechanism we have uncovered is conserved among other tumor types and 
to help us better understand how to target the Wnt5a signaling pathway as a therapeutic 
option for patients who have abnormalities in this pathway. Previous studies showed 
Wnt5a overexpression increased clone formation, migration, invasion, as well as played 
a role in promoting EMT and metastasis in non-small-cell lung cancer (NSCLC) (Wang, 
B. et al 2017). Similarly, loss of E-cadherin and gain of N-cadherin has been reported in 
melanomas transitioning from radial growth phase to vertical growth phase (Danen et al., 
1996; Hsu et al., 1996). Additionally, expression of Wnt5a significantly enhanced 
migration, proliferation, and invasiveness in pancreatic cancer cells. Wnt5a expression 
was reported to be associated with a modulation of genes associated with EMT in 
pancreatic cells as well (Ripka et al., 2007). Importantly, Wnt5a expression was also 
found to be upregulated early during pancreatic carcinogenesis and in invasive 
pancreatic adenocarcinomas (Ripka et al., 2007). Frizzled2 (Fzd2) and Wnt5a are highly 
expressed in metastatic samples and their expression, along with activation of 
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noncanonical Wnt components like PKC and JNK, correlates with EMT markers 
(Dissanayake et al., 2007). Taken together, these observations and studies suggest the 
Wnt5a signaling pathway could not only be contributing to EMT in melanoma but other 
cancers as well (Dissanayake et al., 2007; Jordan et al., 2013; Scheel et al., 2011). 
Investigating the details of how Wnt5a expression is driving epithelial-mesenchymal 
transition can help us better understand its role in EMT and identifying how to prevent 
Wnt5a from promoting EMT in cancer patients. These findings can help us not only 
develop novel therapies but also develop better therapies for patients who experience 
disease recurrence and chemoresistance from EMT, for those who develop EMT 
induced chemoresistance, for example (Fischer et al., 2015). 
Inhibition of the Wnt5a signaling pathway has been previously proposed as a 
novel treatment for cancer patients. This thesis corroborates those proposals and even 
emphasizes how large of a role Wnt5a signaling plays in not only melanoma metastasis, 
but also likely is Wnt5a’s role in other cancer types. Patients with abnormalities in this 
signaling pathway or patients who either do not respond or respond negatively to the 
current standard of care, which includes BRAF inhibitors, among other treatments are in 
dire need of more targeted therapies. There are numerous possibilities of targets within 
this pathway, all with certain benefits and potential pitfalls, and some that may prove 
more effective than others. One option includes inhibition of Wnt5a signaling using Box5 
for patients with tumors with elevated Wnt5a expression. Wnt5a has been shown to play 
a role in resistance to BRAF inhibitors in melanoma patients. Treatment of six BRAF 
mutant melanoma cell lines with increasing does of BRAF inhibitor PLX4032 resulted in 
three cell lines developing resistance to PLX4032 while upregulating expression of 
Wnt5a and activating MAPK signaling (Tap et al., 2010). Another study showed a 
positive correlation between Wnt5a expression and BRAFi resistance (O’Connell et al., 
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2013). Stimulating the cells with recombinant Wnt5a increased BRAFi resistance. 
Knockdown of co-receptor ROR2 increased response to BRAF inhibitor PLX4720 
(O’Connell et al., 2013). These results suggest Wnt5a signaling plays a role in cancer 
cells developing resistance to BRAF inhibitors and targeting the Wnt5a pathway, in this 
case through knockdown or ROR2, results in a better response to BRAF inhibitor 
PLX4720. The authors tied these results to clinical data they obtained on patients 
demonstrating patients who relapsed while on BRAFi therapy showed increased 
positivity for Wnt5a expression, indicating a role for Wnt5a in developing BRAFi 
resistance (O’Connell et al., 2013). A similar observation was reported in BRAFi-
resistant melanoma tumors from another study, where 7 of the 11 patients showed 
increased Wnt5a expression compared to pretreated samples (Anastas et al., 2014). 
These studies suggest that inhibition of Wnt5a signaling might present as a viable co-
treatment option for those patients undergoing BRAF inhibitor therapies as a 
supplemental therapy. Another possibility to inhibit this pathway in patients is inhibition of 
LOK kinase activity by BI-D1870 treatment or development of a more specific inhibitor to 
LOK. Inhibition of polo-like kinase 1, of which LOK has been shown to be an upstream 
regulator of, has been proposed as a possible target for cancer therapy (Walter et al., 
2003; Strebhardt, K. and Ullrich, A., 2006). However, since LOK plays a diverse role in 
the cell and inhibition of LOK may include a larger set of side effects. Wnt5a treatment 
for BRAFi-resistant melanoma has been previously proposed (Prasad et al., 2015), but 
inhibition of APT1 activity as a therapy for cancer patients is a novel idea that is 
supported by the evidence presented in this thesis and is worth investigating further. The 
APT1 specific inhibitor, ML348, has been more recently developed and tested in vitro 
(Won et al., 2016). However, testing ML348 efficacy in vivo by using mouse models of 
cancer progression and metastasis and ultimately how patients respond to inhibition with 
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ML348 in a clinical setting is imperative to help us understand if APT1 inhibition is a 
viable human therapy for cancer patients. By inhibiting APT1 activity, we can inhibit the 
downstream Wnt5a signaling events that have been shown to drive melanoma 
metastasis.  
 
CONCLUDING REMARKS 
 Here, we uncover the mechanistic details of the downstream signaling events 
that contribute to Wnt5a mediated metastatic melanoma. Targeting the Wnt5a/APT1 
signaling axis, specifically through APT1 inhibition, would be a novel approach to 
treating Wnt5a driven melanoma. There is also the potential for a wider range of 
applications from the findings in this thesis for treating other types of Wnt5a driven 
cancers which have either upregulated Wnt5a or ROR2 expression, other tumor types 
with mutations in APT1, or even those with elevated LOK expression or LOK mutations. 
Metastatic melanoma patients are in dire need of targeted therapies to the players 
involved in this signaling axis and inhibition of APT1 activity might be a viable option to 
explore further. Our goal is for the findings obtained in this thesis to contribute to the 
scientific community in helping to understand why and how cancers hijack the Wnt5a 
signaling pathway and how we can best serve patients in the future. Below is a 
schematic of the model we have proposed in this thesis.  
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